id	sid	tid	token	lemma	pos
cord-351517-npcuo1ld	1	1	key	key	JJ
cord-351517-npcuo1ld	1	2	:	:	:
cord-351517-npcuo1ld	1	3	cord-351517-npcuo1ld	cord-351517-npcuo1ld	CD
cord-351517-npcuo1ld	1	4	authors	author	NNS
cord-351517-npcuo1ld	1	5	:	:	:
cord-351517-npcuo1ld	1	6	Gale	Gale	NNP
cord-351517-npcuo1ld	1	7	,	,	,
cord-351517-npcuo1ld	1	8	Robert	Robert	NNP
cord-351517-npcuo1ld	1	9	Peter	Peter	NNP
cord-351517-npcuo1ld	1	10	;	;	:
cord-351517-npcuo1ld	1	11	Lazarus	Lazarus	NNP
cord-351517-npcuo1ld	1	12	,	,	,
cord-351517-npcuo1ld	1	13	Hillard	Hillard	NNP
cord-351517-npcuo1ld	1	14	M.	M.	NNP
cord-351517-npcuo1ld	1	15	title	title	NN
cord-351517-npcuo1ld	1	16	:	:	:
cord-351517-npcuo1ld	1	17	Liaisons	Liaisons	NNP
cord-351517-npcuo1ld	1	18	Dangereuses	dangereuse	NNS
cord-351517-npcuo1ld	1	19	?	?	.
cord-351517-npcuo1ld	2	1	new	new	JJ
cord-351517-npcuo1ld	2	2	drugs	drug	NNS
cord-351517-npcuo1ld	2	3	,	,	,
cord-351517-npcuo1ld	2	4	physicians	physician	NNS
cord-351517-npcuo1ld	2	5	and	and	CC
cord-351517-npcuo1ld	2	6	the	the	DT
cord-351517-npcuo1ld	2	7	drug	drug	NN
cord-351517-npcuo1ld	2	8	industry	industry	NN
cord-351517-npcuo1ld	2	9	date	date	NN
cord-351517-npcuo1ld	2	10	:	:	:
cord-351517-npcuo1ld	2	11	2020	2020	CD
cord-351517-npcuo1ld	2	12	-	-	HYPH
cord-351517-npcuo1ld	2	13	07	07	CD
cord-351517-npcuo1ld	2	14	-	-	HYPH
cord-351517-npcuo1ld	2	15	01	01	CD
cord-351517-npcuo1ld	2	16	journal	journal	NN
cord-351517-npcuo1ld	2	17	:	:	:
cord-351517-npcuo1ld	2	18	Bone	Bone	NNP
cord-351517-npcuo1ld	2	19	Marrow	Marrow	NNP
cord-351517-npcuo1ld	2	20	Transplant	transplant	NN
cord-351517-npcuo1ld	2	21	DOI	doi	NN
cord-351517-npcuo1ld	2	22	:	:	:
cord-351517-npcuo1ld	2	23	10.1038	10.1038	CD
cord-351517-npcuo1ld	2	24	/	/	SYM
cord-351517-npcuo1ld	2	25	s41409	s41409	NNP
cord-351517-npcuo1ld	2	26	-	-	HYPH
cord-351517-npcuo1ld	2	27	020	020	CD
cord-351517-npcuo1ld	3	1	-0988	-0988	:
cord-351517-npcuo1ld	3	2	-	-	HYPH
cord-351517-npcuo1ld	3	3	0	0	CD
cord-351517-npcuo1ld	3	4	sha	sha	NN
cord-351517-npcuo1ld	3	5	:	:	:
cord-351517-npcuo1ld	4	1	45f233468da5e9467846ae46d366b788c60e8d8c	45f233468da5e9467846ae46d366b788c60e8d8c	NNP
cord-351517-npcuo1ld	4	2	doc_id	doc_id	CD
cord-351517-npcuo1ld	4	3	:	:	:
cord-351517-npcuo1ld	4	4	351517	351517	CD
cord-351517-npcuo1ld	5	1	cord_uid	cord_uid	NN
cord-351517-npcuo1ld	5	2	:	:	:
cord-351517-npcuo1ld	6	1	npcuo1ld	npcuo1ld	JJ
cord-351517-npcuo1ld	6	2	nan	nan	NNP
cord-351517-npcuo1ld	6	3	US	US	NNP
cord-351517-npcuo1ld	6	4	Food	Food	NNP
cord-351517-npcuo1ld	6	5	and	and	CC
cord-351517-npcuo1ld	6	6	Drug	Drug	NNP
cord-351517-npcuo1ld	6	7	Administration	Administration	NNP
cord-351517-npcuo1ld	6	8	(	(	-LRB-
cord-351517-npcuo1ld	6	9	FDA	FDA	NNP
cord-351517-npcuo1ld	6	10	)	)	-RRB-
cord-351517-npcuo1ld	6	11	has	have	VBZ
cord-351517-npcuo1ld	6	12	approved	approve	VBN
cord-351517-npcuo1ld	6	13	record	record	JJ
cord-351517-npcuo1ld	6	14	numbers	number	NNS
cord-351517-npcuo1ld	6	15	of	of	IN
cord-351517-npcuo1ld	6	16	new	new	JJ
cord-351517-npcuo1ld	6	17	cancer	cancer	NN
cord-351517-npcuo1ld	6	18	drugs	drug	NNS
cord-351517-npcuo1ld	6	19	in	in	IN
cord-351517-npcuo1ld	6	20	recent	recent	JJ
cord-351517-npcuo1ld	6	21	years	year	NNS
cord-351517-npcuo1ld	6	22	.	.	.
cord-351517-npcuo1ld	7	1	Many	many	JJ
cord-351517-npcuo1ld	7	2	are	be	VBP
cord-351517-npcuo1ld	7	3	relevant	relevant	JJ
cord-351517-npcuo1ld	7	4	to	to	IN
cord-351517-npcuo1ld	7	5	readers	reader	NNS
cord-351517-npcuo1ld	7	6	of	of	IN
cord-351517-npcuo1ld	7	7	BONE	BONE	NNP
cord-351517-npcuo1ld	7	8	MARROW	marrow	NN
cord-351517-npcuo1ld	7	9	TRANSPLAN	TRANSPLAN	NNP
cord-351517-npcuo1ld	7	10	-	-	HYPH
cord-351517-npcuo1ld	7	11	TATION	TATION	NNP
cord-351517-npcuo1ld	7	12	who	who	WP
cord-351517-npcuo1ld	7	13	treat	treat	VBP
cord-351517-npcuo1ld	7	14	acute	acute	JJ
cord-351517-npcuo1ld	7	15	myeloid	myeloid	NN
cord-351517-npcuo1ld	7	16	leukaemia	leukaemia	NN
cord-351517-npcuo1ld	7	17	(	(	-LRB-
cord-351517-npcuo1ld	7	18	AML	AML	NNP
cord-351517-npcuo1ld	7	19	)	)	-RRB-
cord-351517-npcuo1ld	7	20	including	include	VBG
cord-351517-npcuo1ld	7	21	midostarin	midostarin	NNP
cord-351517-npcuo1ld	7	22	,	,	,
cord-351517-npcuo1ld	7	23	gilteritinib	gilteritinib	NN
cord-351517-npcuo1ld	7	24	,	,	,
cord-351517-npcuo1ld	7	25	venetoclax	venetoclax	NNP
cord-351517-npcuo1ld	7	26	,	,	,
cord-351517-npcuo1ld	7	27	enasideinib	enasideinib	NNP
cord-351517-npcuo1ld	7	28	,	,	,
cord-351517-npcuo1ld	7	29	ivosidenib	ivosidenib	NNP
cord-351517-npcuo1ld	7	30	,	,	,
cord-351517-npcuo1ld	7	31	glasdegib	glasdegib	NNP
cord-351517-npcuo1ld	7	32	,	,	,
cord-351517-npcuo1ld	7	33	acute	acute	JJ
cord-351517-npcuo1ld	7	34	lymphoblastic	lymphoblastic	JJ
cord-351517-npcuo1ld	7	35	leukaemia	leukaemia	NN
cord-351517-npcuo1ld	7	36	including	include	VBG
cord-351517-npcuo1ld	7	37	inotuzumab	inotuzumab	NNS
cord-351517-npcuo1ld	7	38	ozogamicin	ozogamicin	NNS
cord-351517-npcuo1ld	7	39	,	,	,
cord-351517-npcuo1ld	7	40	blinatumomab	blinatumomab	NNP
cord-351517-npcuo1ld	7	41	,	,	,
cord-351517-npcuo1ld	7	42	dasatinib	dasatinib	NN
cord-351517-npcuo1ld	7	43	,	,	,
cord-351517-npcuo1ld	7	44	ponatinib	ponatinib	NN
cord-351517-npcuo1ld	7	45	and	and	CC
cord-351517-npcuo1ld	7	46	tisagenlecleucel	tisagenlecleucel	JJ
cord-351517-npcuo1ld	7	47	,	,	,
cord-351517-npcuo1ld	7	48	chronic	chronic	JJ
cord-351517-npcuo1ld	7	49	myeloid	myeloid	NN
cord-351517-npcuo1ld	7	50	leukaemia	leukaemia	NN
cord-351517-npcuo1ld	7	51	including	include	VBG
cord-351517-npcuo1ld	7	52	ponatinib	ponatinib	NNP
cord-351517-npcuo1ld	7	53	and	and	CC
cord-351517-npcuo1ld	7	54	bosutinib	bosutinib	NNP
cord-351517-npcuo1ld	7	55	,	,	,
cord-351517-npcuo1ld	7	56	plasma	plasma	NN
cord-351517-npcuo1ld	7	57	cell	cell	NN
cord-351517-npcuo1ld	7	58	myeloma	myeloma	NN
cord-351517-npcuo1ld	7	59	including	include	VBG
cord-351517-npcuo1ld	7	60	daratumumab	daratumumab	NNP
cord-351517-npcuo1ld	7	61	,	,	,
cord-351517-npcuo1ld	7	62	selinexor	selinexor	NNP
cord-351517-npcuo1ld	7	63	,	,	,
cord-351517-npcuo1ld	7	64	elotuzumab	elotuzumab	NNP
cord-351517-npcuo1ld	7	65	,	,	,
cord-351517-npcuo1ld	7	66	panobinostat	panobinostat	NNP
cord-351517-npcuo1ld	7	67	and	and	CC
cord-351517-npcuo1ld	7	68	ixazomib	ixazomib	NNP
cord-351517-npcuo1ld	7	69	,	,	,
cord-351517-npcuo1ld	7	70	chronic	chronic	JJ
cord-351517-npcuo1ld	7	71	lymphocytic	lymphocytic	JJ
cord-351517-npcuo1ld	7	72	leukaemia	leukaemia	NN
cord-351517-npcuo1ld	7	73	including	include	VBG
cord-351517-npcuo1ld	7	74	ibrutinib	ibrutinib	NNP
cord-351517-npcuo1ld	7	75	,	,	,
cord-351517-npcuo1ld	7	76	idelalisib	idelalisib	NNP
cord-351517-npcuo1ld	7	77	and	and	CC
cord-351517-npcuo1ld	7	78	ofatumumab	ofatumumab	NNP
cord-351517-npcuo1ld	7	79	,	,	,
cord-351517-npcuo1ld	7	80	lymphoma	lymphoma	NN
cord-351517-npcuo1ld	7	81	including	include	VBG
cord-351517-npcuo1ld	7	82	vorinostat	vorinostat	NNP
cord-351517-npcuo1ld	7	83	,	,	,
cord-351517-npcuo1ld	7	84	mogamulizumab	mogamulizumab	NNP
cord-351517-npcuo1ld	7	85	-	-	HYPH
cord-351517-npcuo1ld	7	86	kpkc	kpkc	NNP
cord-351517-npcuo1ld	7	87	,	,	,
cord-351517-npcuo1ld	7	88	polatuzumab	polatuzumab	NNP
cord-351517-npcuo1ld	7	89	vedotin	vedotin	NNP
cord-351517-npcuo1ld	7	90	-	-	HYPH
cord-351517-npcuo1ld	7	91	piiq	piiq	NNP
cord-351517-npcuo1ld	7	92	,	,	,
cord-351517-npcuo1ld	7	93	acabrutinib	acabrutinib	NNP
cord-351517-npcuo1ld	7	94	,	,	,
cord-351517-npcuo1ld	7	95	brentuximab	brentuximab	NNP
cord-351517-npcuo1ld	7	96	vedotin	vedotin	NNP
cord-351517-npcuo1ld	7	97	,	,	,
cord-351517-npcuo1ld	7	98	zanubrutinib	zanubrutinib	NNP
cord-351517-npcuo1ld	7	99	,	,	,
cord-351517-npcuo1ld	7	100	axicabtagene	axicabtagene	NNP
cord-351517-npcuo1ld	7	101	ciloleucel	ciloleucel	NNP
cord-351517-npcuo1ld	7	102	and	and	CC
cord-351517-npcuo1ld	7	103	tisagenlecleucel	tisagenlecleucel	NNP
cord-351517-npcuo1ld	7	104	,	,	,
cord-351517-npcuo1ld	7	105	myeloproliferative	myeloproliferative	JJ
cord-351517-npcuo1ld	7	106	neoplasm	neoplasm	NN
cord-351517-npcuo1ld	7	107	(	(	-LRB-
cord-351517-npcuo1ld	7	108	MPN)-associated	mpn)-associate	VBN
cord-351517-npcuo1ld	7	109	myelofibrosis	myelofibrosis	NNP
cord-351517-npcuo1ld	7	110	including	include	VBG
cord-351517-npcuo1ld	7	111	fedratinib	fedratinib	NNP
cord-351517-npcuo1ld	7	112	and	and	CC
cord-351517-npcuo1ld	7	113	acute	acute	JJ
cord-351517-npcuo1ld	7	114	and	and	CC
cord-351517-npcuo1ld	7	115	chronic	chronic	JJ
cord-351517-npcuo1ld	7	116	graftversus	graftversus	NN
cord-351517-npcuo1ld	7	117	-	-	HYPH
cord-351517-npcuo1ld	7	118	host	host	NN
cord-351517-npcuo1ld	7	119	disease	disease	NN
cord-351517-npcuo1ld	7	120	(	(	-LRB-
cord-351517-npcuo1ld	7	121	GvHD	GvHD	NNP
cord-351517-npcuo1ld	7	122	)	)	-RRB-
cord-351517-npcuo1ld	7	123	including	include	VBG
cord-351517-npcuo1ld	7	124	ibrutinib	ibrutinib	NN
cord-351517-npcuo1ld	7	125	and	and	CC
cord-351517-npcuo1ld	7	126	ruxolitinib	ruxolitinib	NNP
cord-351517-npcuo1ld	7	127	.	.	.
cord-351517-npcuo1ld	8	1	This	this	DT
cord-351517-npcuo1ld	8	2	is	be	VBZ
cord-351517-npcuo1ld	8	3	extraordinarily	extraordinarily	RB
cord-351517-npcuo1ld	8	4	good	good	JJ
cord-351517-npcuo1ld	8	5	news	news	NN
cord-351517-npcuo1ld	8	6	but	but	CC
cord-351517-npcuo1ld	8	7	raises	raise	VBZ
cord-351517-npcuo1ld	8	8	questions	question	NNS
cord-351517-npcuo1ld	8	9	whether	whether	IN
cord-351517-npcuo1ld	8	10	everyone	everyone	NN
cord-351517-npcuo1ld	8	11	receiving	receive	VBG
cord-351517-npcuo1ld	8	12	a	a	DT
cord-351517-npcuo1ld	8	13	haematopoietic	haematopoietic	JJ
cord-351517-npcuo1ld	8	14	cell	cell	NN
cord-351517-npcuo1ld	8	15	transplant	transplant	NN
cord-351517-npcuo1ld	8	16	needs	need	NNS
cord-351517-npcuo1ld	8	17	and/or	and/or	CC
cord-351517-npcuo1ld	8	18	benefits	benefit	NNS
cord-351517-npcuo1ld	8	19	from	from	IN
cord-351517-npcuo1ld	8	20	these	these	DT
cord-351517-npcuo1ld	8	21	new	new	JJ
cord-351517-npcuo1ld	8	22	drugs	drug	NNS
cord-351517-npcuo1ld	8	23	and	and	CC
cord-351517-npcuo1ld	8	24	whether	whether	IN
cord-351517-npcuo1ld	8	25	physicians	physician	NNS
cord-351517-npcuo1ld	8	26	were	be	VBD
cord-351517-npcuo1ld	8	27	complicit	complicit	JJ
cord-351517-npcuo1ld	8	28	in	in	IN
cord-351517-npcuo1ld	8	29	promoting	promote	VBG
cord-351517-npcuo1ld	8	30	their	-PRON-	PRP$
cord-351517-npcuo1ld	8	31	approval	approval	NN
cord-351517-npcuo1ld	8	32	and	and	CC
cord-351517-npcuo1ld	8	33	subsequent	subsequent	JJ
cord-351517-npcuo1ld	8	34	use	use	NN
cord-351517-npcuo1ld	8	35	.	.	.
cord-351517-npcuo1ld	9	1	These	these	DT
cord-351517-npcuo1ld	9	2	questions	question	NNS
cord-351517-npcuo1ld	9	3	are	be	VBP
cord-351517-npcuo1ld	9	4	especially	especially	RB
cord-351517-npcuo1ld	9	5	important	important	JJ
cord-351517-npcuo1ld	9	6	in	in	IN
cord-351517-npcuo1ld	9	7	developing	develop	VBG
cord-351517-npcuo1ld	9	8	countries	country	NNS
cord-351517-npcuo1ld	9	9	where	where	WRB
cord-351517-npcuo1ld	9	10	many	many	JJ
cord-351517-npcuo1ld	9	11	of	of	IN
cord-351517-npcuo1ld	9	12	these	these	DT
cord-351517-npcuo1ld	9	13	new	new	JJ
cord-351517-npcuo1ld	9	14	drugs	drug	NNS
cord-351517-npcuo1ld	9	15	are	be	VBP
cord-351517-npcuo1ld	9	16	not	not	RB
cord-351517-npcuo1ld	9	17	yet	yet	RB
cord-351517-npcuo1ld	9	18	or	or	CC
cord-351517-npcuo1ld	9	19	may	may	MD
cord-351517-npcuo1ld	9	20	ever	ever	RB
cord-351517-npcuo1ld	9	21	be	be	VB
cord-351517-npcuo1ld	9	22	approved	approve	VBN
cord-351517-npcuo1ld	9	23	,	,	,
cord-351517-npcuo1ld	9	24	available	available	JJ
cord-351517-npcuo1ld	9	25	and/or	and/or	CC
cord-351517-npcuo1ld	9	26	affordable	affordable	JJ
cord-351517-npcuo1ld	9	27	.	.	.
cord-351517-npcuo1ld	10	1	First	first	RB
cord-351517-npcuo1ld	10	2	,	,	,
cord-351517-npcuo1ld	10	3	do	do	VB
cord-351517-npcuo1ld	10	4	these	these	DT
cord-351517-npcuo1ld	10	5	new	new	JJ
cord-351517-npcuo1ld	10	6	drugs	drug	NNS
cord-351517-npcuo1ld	10	7	really	really	RB
cord-351517-npcuo1ld	10	8	improve	improve	VBP
cord-351517-npcuo1ld	10	9	survival	survival	NN
cord-351517-npcuo1ld	10	10	?	?	.
cord-351517-npcuo1ld	11	1	For	for	IN
cord-351517-npcuo1ld	11	2	example	example	NN
cord-351517-npcuo1ld	11	3	,	,	,
cord-351517-npcuo1ld	11	4	many	many	JJ
cord-351517-npcuo1ld	11	5	approvals	approval	NNS
cord-351517-npcuo1ld	11	6	in	in	IN
cord-351517-npcuo1ld	11	7	AML	AML	NNP
cord-351517-npcuo1ld	11	8	relevant	relevant	JJ
cord-351517-npcuo1ld	11	9	to	to	IN
cord-351517-npcuo1ld	11	10	haematopoietic	haematopoietic	JJ
cord-351517-npcuo1ld	11	11	cell	cell	NN
cord-351517-npcuo1ld	11	12	transplantation	transplantation	NN
cord-351517-npcuo1ld	11	13	were	be	VBD
cord-351517-npcuo1ld	11	14	based	base	VBN
cord-351517-npcuo1ld	11	15	on	on	IN
cord-351517-npcuo1ld	11	16	data	datum	NNS
cord-351517-npcuo1ld	11	17	from	from	IN
cord-351517-npcuo1ld	11	18	small	small	JJ
cord-351517-npcuo1ld	11	19	,	,	,
cord-351517-npcuo1ld	11	20	sometimes	sometimes	RB
cord-351517-npcuo1ld	11	21	uncontrolled	uncontrolled	JJ
cord-351517-npcuo1ld	11	22	phase-2	phase-2	NNP
cord-351517-npcuo1ld	11	23	studies	study	NNS
cord-351517-npcuo1ld	11	24	.	.	.
cord-351517-npcuo1ld	12	1	Also	also	RB
cord-351517-npcuo1ld	12	2	,	,	,
cord-351517-npcuo1ld	12	3	many	many	JJ
cord-351517-npcuo1ld	12	4	regular	regular	JJ
cord-351517-npcuo1ld	12	5	approvals	approval	NNS
cord-351517-npcuo1ld	12	6	were	be	VBD
cord-351517-npcuo1ld	12	7	based	base	VBN
cord-351517-npcuo1ld	12	8	on	on	IN
cord-351517-npcuo1ld	12	9	surrogate	surrogate	JJ
cord-351517-npcuo1ld	12	10	endpoints	endpoint	NNS
cord-351517-npcuo1ld	12	11	such	such	JJ
cord-351517-npcuo1ld	12	12	as	as	IN
cord-351517-npcuo1ld	12	13	complete	complete	JJ
cord-351517-npcuo1ld	12	14	or	or	CC
cord-351517-npcuo1ld	12	15	overall	overall	JJ
cord-351517-npcuo1ld	12	16	response	response	NN
cord-351517-npcuo1ld	12	17	rate	rate	NN
cord-351517-npcuo1ld	12	18	,	,	,
cord-351517-npcuo1ld	12	19	response	response	NN
cord-351517-npcuo1ld	12	20	duration	duration	NN
cord-351517-npcuo1ld	12	21	and/or	and/or	CC
cord-351517-npcuo1ld	12	22	progression	progression	NN
cord-351517-npcuo1ld	12	23	-	-	HYPH
cord-351517-npcuo1ld	12	24	free	free	JJ
cord-351517-npcuo1ld	12	25	survival	survival	NN
cord-351517-npcuo1ld	12	26	(	(	-LRB-
cord-351517-npcuo1ld	12	27	PFS	PFS	NNP
cord-351517-npcuo1ld	12	28	)	)	-RRB-
cord-351517-npcuo1ld	12	29	rather	rather	RB
cord-351517-npcuo1ld	12	30	than	than	IN
cord-351517-npcuo1ld	12	31	survival	survival	NN
cord-351517-npcuo1ld	12	32	.	.	.
cord-351517-npcuo1ld	13	1	For	for	IN
cord-351517-npcuo1ld	13	2	example	example	NN
cord-351517-npcuo1ld	13	3	,	,	,
cord-351517-npcuo1ld	13	4	between	between	IN
cord-351517-npcuo1ld	13	5	2009	2009	CD
cord-351517-npcuo1ld	13	6	and	and	CC
cord-351517-npcuo1ld	13	7	2014	2014	CD
cord-351517-npcuo1ld	13	8	the	the	DT
cord-351517-npcuo1ld	13	9	US	US	NNP
cord-351517-npcuo1ld	13	10	FDA	FDA	NNP
cord-351517-npcuo1ld	13	11	-	-	HYPH
cord-351517-npcuo1ld	13	12	approved	approve	VBN
cord-351517-npcuo1ld	13	13	83	83	CD
cord-351517-npcuo1ld	13	14	cancer	cancer	NN
cord-351517-npcuo1ld	13	15	drugs	drug	NNS
cord-351517-npcuo1ld	13	16	,	,	,
cord-351517-npcuo1ld	13	17	55	55	CD
cord-351517-npcuo1ld	13	18	based	base	VBN
cord-351517-npcuo1ld	13	19	on	on	IN
cord-351517-npcuo1ld	13	20	surrogate	surrogate	JJ
cord-351517-npcuo1ld	13	21	outcomes	outcome	NNS
cord-351517-npcuo1ld	13	22	including	include	VBG
cord-351517-npcuo1ld	13	23	31	31	CD
cord-351517-npcuo1ld	13	24	based	base	VBN
cord-351517-npcuo1ld	13	25	on	on	IN
cord-351517-npcuo1ld	13	26	overall	overall	JJ
cord-351517-npcuo1ld	13	27	response	response	NN
cord-351517-npcuo1ld	13	28	rate	rate	NN
cord-351517-npcuo1ld	13	29	and	and	CC
cord-351517-npcuo1ld	13	30	24	24	CD
cord-351517-npcuo1ld	13	31	based	base	VBN
cord-351517-npcuo1ld	13	32	on	on	IN
cord-351517-npcuo1ld	13	33	PFS	PFS	NNP
cord-351517-npcuo1ld	13	34	[	[	-LRB-
cord-351517-npcuo1ld	13	35	1	1	CD
cord-351517-npcuo1ld	13	36	]	]	-RRB-
cord-351517-npcuo1ld	13	37	.	.	.
cord-351517-npcuo1ld	14	1	All	all	DT
cord-351517-npcuo1ld	14	2	accelerated	accelerated	JJ
cord-351517-npcuo1ld	14	3	approvals	approval	NNS
cord-351517-npcuo1ld	14	4	and	and	CC
cord-351517-npcuo1ld	14	5	one	one	CD
cord-351517-npcuo1ld	14	6	-	-	HYPH
cord-351517-npcuo1ld	14	7	half	half	NN
cord-351517-npcuo1ld	14	8	of	of	IN
cord-351517-npcuo1ld	14	9	conventional	conventional	JJ
cord-351517-npcuo1ld	14	10	approvals	approval	NNS
cord-351517-npcuo1ld	14	11	were	be	VBD
cord-351517-npcuo1ld	14	12	based	base	VBN
cord-351517-npcuo1ld	14	13	on	on	IN
cord-351517-npcuo1ld	14	14	treatment	treatment	NN
cord-351517-npcuo1ld	14	15	effects	effect	NNS
cord-351517-npcuo1ld	14	16	with	with	IN
cord-351517-npcuo1ld	14	17	surrogate	surrogate	JJ
cord-351517-npcuo1ld	14	18	outcomes	outcome	NNS
cord-351517-npcuo1ld	14	19	.	.	.
cord-351517-npcuo1ld	15	1	In	in	IN
cord-351517-npcuo1ld	15	2	a	a	DT
cord-351517-npcuo1ld	15	3	recent	recent	JJ
cord-351517-npcuo1ld	15	4	review	review	NN
cord-351517-npcuo1ld	15	5	fewer	few	JJR
cord-351517-npcuo1ld	15	6	than	than	IN
cord-351517-npcuo1ld	15	7	one	one	CD
cord-351517-npcuo1ld	15	8	-	-	HYPH
cord-351517-npcuo1ld	15	9	half	half	NN
cord-351517-npcuo1ld	15	10	of	of	IN
cord-351517-npcuo1ld	15	11	drugs	drug	NNS
cord-351517-npcuo1ld	15	12	approved	approve	VBN
cord-351517-npcuo1ld	15	13	based	base	VBN
cord-351517-npcuo1ld	15	14	on	on	IN
cord-351517-npcuo1ld	15	15	a	a	DT
cord-351517-npcuo1ld	15	16	PFS	PFS	NNP
cord-351517-npcuo1ld	15	17	endpoint	endpoint	NN
cord-351517-npcuo1ld	15	18	were	be	VBD
cord-351517-npcuo1ld	15	19	shown	show	VBN
cord-351517-npcuo1ld	15	20	to	to	TO
cord-351517-npcuo1ld	15	21	improve	improve	VB
cord-351517-npcuo1ld	15	22	survival	survival	NN
cord-351517-npcuo1ld	15	23	or	or	CC
cord-351517-npcuo1ld	15	24	quality	quality	NN
cord-351517-npcuo1ld	15	25	-	-	HYPH
cord-351517-npcuo1ld	15	26	of	of	IN
cord-351517-npcuo1ld	15	27	-	-	HYPH
cord-351517-npcuo1ld	15	28	life	life	NN
cord-351517-npcuo1ld	15	29	(	(	-LRB-
cord-351517-npcuo1ld	15	30	QoL	qol	NN
cord-351517-npcuo1ld	15	31	)	)	-RRB-
cord-351517-npcuo1ld	15	32	[	[	-LRB-
cord-351517-npcuo1ld	15	33	2	2	CD
cord-351517-npcuo1ld	15	34	]	]	-RRB-
cord-351517-npcuo1ld	15	35	.	.	.
cord-351517-npcuo1ld	16	1	Similarly	similarly	RB
cord-351517-npcuo1ld	16	2	,	,	,
cord-351517-npcuo1ld	16	3	between	between	IN
cord-351517-npcuo1ld	16	4	2009	2009	CD
cord-351517-npcuo1ld	16	5	and	and	CC
cord-351517-npcuo1ld	16	6	2013	2013	CD
cord-351517-npcuo1ld	16	7	the	the	DT
cord-351517-npcuo1ld	16	8	European	European	NNP
cord-351517-npcuo1ld	16	9	Medicines	Medicines	NNPS
cord-351517-npcuo1ld	16	10	Agency	Agency	NNP
cord-351517-npcuo1ld	16	11	(	(	-LRB-
cord-351517-npcuo1ld	16	12	EMA	EMA	NNP
cord-351517-npcuo1ld	16	13	)	)	-RRB-
cord-351517-npcuo1ld	16	14	approved	approve	VBD
cord-351517-npcuo1ld	16	15	48	48	CD
cord-351517-npcuo1ld	16	16	cancer	cancer	NN
cord-351517-npcuo1ld	16	17	drugs	drug	NNS
cord-351517-npcuo1ld	17	1	only	only	RB
cord-351517-npcuo1ld	17	2	one	one	CD
cord-351517-npcuo1ld	17	3	-	-	HYPH
cord-351517-npcuo1ld	17	4	half	half	NN
cord-351517-npcuo1ld	17	5	of	of	IN
cord-351517-npcuo1ld	17	6	which	which	WDT
cord-351517-npcuo1ld	17	7	were	be	VBD
cord-351517-npcuo1ld	17	8	proved	prove	VBN
cord-351517-npcuo1ld	17	9	to	to	TO
cord-351517-npcuo1ld	17	10	increase	increase	VB
cord-351517-npcuo1ld	17	11	survival	survival	NN
cord-351517-npcuo1ld	17	12	or	or	CC
cord-351517-npcuo1ld	17	13	improve	improve	VB
cord-351517-npcuo1ld	17	14	QoL	qol	NN
cord-351517-npcuo1ld	17	15	[	[	-LRB-
cord-351517-npcuo1ld	17	16	3	3	CD
cord-351517-npcuo1ld	17	17	]	]	-RRB-
cord-351517-npcuo1ld	17	18	.	.	.
cord-351517-npcuo1ld	18	1	Another	another	DT
cord-351517-npcuo1ld	18	2	problem	problem	NN
cord-351517-npcuo1ld	18	3	with	with	IN
cord-351517-npcuo1ld	18	4	several	several	JJ
cord-351517-npcuo1ld	18	5	new	new	JJ
cord-351517-npcuo1ld	18	6	drug	drug	NN
cord-351517-npcuo1ld	18	7	approvals	approval	NNS
cord-351517-npcuo1ld	18	8	is	be	VBZ
cord-351517-npcuo1ld	18	9	the	the	DT
cord-351517-npcuo1ld	18	10	choice	choice	NN
cord-351517-npcuo1ld	18	11	of	of	IN
cord-351517-npcuo1ld	18	12	an	an	DT
cord-351517-npcuo1ld	18	13	inappropriate	inappropriate	JJ
cord-351517-npcuo1ld	18	14	comparator	comparator	NN
cord-351517-npcuo1ld	18	15	therapy	therapy	NN
cord-351517-npcuo1ld	18	16	in	in	IN
cord-351517-npcuo1ld	18	17	randomized	randomized	JJ
cord-351517-npcuo1ld	18	18	phase-2	phase-2	NNP
cord-351517-npcuo1ld	18	19	or	or	CC
cord-351517-npcuo1ld	18	20	phase-3	phase-3	NNP
cord-351517-npcuo1ld	18	21	trials	trial	NNS
cord-351517-npcuo1ld	18	22	.	.	.
cord-351517-npcuo1ld	19	1	Finally	finally	RB
cord-351517-npcuo1ld	19	2	,	,	,
cord-351517-npcuo1ld	19	3	many	many	JJ
cord-351517-npcuo1ld	19	4	of	of	IN
cord-351517-npcuo1ld	19	5	these	these	DT
cord-351517-npcuo1ld	19	6	approvals	approval	NNS
cord-351517-npcuo1ld	19	7	were	be	VBD
cord-351517-npcuo1ld	19	8	based	base	VBN
cord-351517-npcuo1ld	19	9	on	on	IN
cord-351517-npcuo1ld	19	10	analyses	analysis	NNS
cord-351517-npcuo1ld	19	11	of	of	IN
cord-351517-npcuo1ld	19	12	hazard	hazard	NN
cord-351517-npcuo1ld	19	13	ratios	ratio	NNS
cord-351517-npcuo1ld	19	14	rather	rather	RB
cord-351517-npcuo1ld	19	15	than	than	IN
cord-351517-npcuo1ld	19	16	a	a	DT
cord-351517-npcuo1ld	19	17	preferred	preferred	JJ
cord-351517-npcuo1ld	19	18	mean	mean	NN
cord-351517-npcuo1ld	19	19	restricted	restricted	JJ
cord-351517-npcuo1ld	19	20	survival	survival	NN
cord-351517-npcuo1ld	19	21	time	time	NN
cord-351517-npcuo1ld	19	22	[	[	-LRB-
cord-351517-npcuo1ld	19	23	4	4	CD
cord-351517-npcuo1ld	19	24	]	]	-RRB-
cord-351517-npcuo1ld	19	25	.	.	.
cord-351517-npcuo1ld	20	1	Another	another	DT
cord-351517-npcuo1ld	20	2	issue	issue	NN
cord-351517-npcuo1ld	20	3	is	be	VBZ
cord-351517-npcuo1ld	20	4	the	the	DT
cord-351517-npcuo1ld	20	5	magnitude	magnitude	NN
cord-351517-npcuo1ld	20	6	of	of	IN
cord-351517-npcuo1ld	20	7	benefit	benefit	NN
cord-351517-npcuo1ld	20	8	conferred	confer	VBN
cord-351517-npcuo1ld	20	9	by	by	IN
cord-351517-npcuo1ld	20	10	new	new	JJ
cord-351517-npcuo1ld	20	11	drugs	drug	NNS
cord-351517-npcuo1ld	20	12	like	like	IN
cord-351517-npcuo1ld	20	13	midostaurin	midostaurin	NNP
cord-351517-npcuo1ld	20	14	and	and	CC
cord-351517-npcuo1ld	20	15	how	how	WRB
cord-351517-npcuo1ld	20	16	they	-PRON-	PRP
cord-351517-npcuo1ld	20	17	should	should	MD
cord-351517-npcuo1ld	20	18	be	be	VB
cord-351517-npcuo1ld	20	19	used	use	VBN
cord-351517-npcuo1ld	20	20	in	in	IN
cord-351517-npcuo1ld	20	21	persons	person	NNS
cord-351517-npcuo1ld	20	22	with	with	IN
cord-351517-npcuo1ld	20	23	AML	AML	NNP
cord-351517-npcuo1ld	20	24	with	with	IN
cord-351517-npcuo1ld	20	25	a	a	DT
cord-351517-npcuo1ld	20	26	FLT3	FLT3	NNP
cord-351517-npcuo1ld	20	27	mutation	mutation	NN
cord-351517-npcuo1ld	20	28	.	.	.
cord-351517-npcuo1ld	21	1	In	in	IN
cord-351517-npcuo1ld	21	2	the	the	DT
cord-351517-npcuo1ld	21	3	randomized	randomized	JJ
cord-351517-npcuo1ld	21	4	study	study	NN
cord-351517-npcuo1ld	21	5	of	of	IN
cord-351517-npcuo1ld	21	6	midostaurin	midostaurin	NNP
cord-351517-npcuo1ld	21	7	57	57	CD
cord-351517-npcuo1ld	21	8	percent	percent	NN
cord-351517-npcuo1ld	21	9	of	of	IN
cord-351517-npcuo1ld	21	10	subjects	subject	NNS
cord-351517-npcuo1ld	21	11	received	receive	VBD
cord-351517-npcuo1ld	21	12	an	an	DT
cord-351517-npcuo1ld	21	13	allotransplant	allotransplant	NN
cord-351517-npcuo1ld	21	14	with	with	IN
cord-351517-npcuo1ld	21	15	an	an	DT
cord-351517-npcuo1ld	21	16	important	important	JJ
cord-351517-npcuo1ld	21	17	imbalance	imbalance	NN
cord-351517-npcuo1ld	21	18	between	between	IN
cord-351517-npcuo1ld	21	19	the	the	DT
cord-351517-npcuo1ld	21	20	midostaurin	midostaurin	NN
cord-351517-npcuo1ld	21	21	and	and	CC
cord-351517-npcuo1ld	21	22	placebo	placebo	NN
cord-351517-npcuo1ld	21	23	cohorts	cohort	NNS
cord-351517-npcuo1ld	21	24	in	in	IN
cord-351517-npcuo1ld	21	25	subjects	subject	NNS
cord-351517-npcuo1ld	21	26	transplanted	transplant	VBN
cord-351517-npcuo1ld	21	27	in	in	IN
cord-351517-npcuo1ld	21	28	1st	1st	JJ
cord-351517-npcuo1ld	21	29	complete	complete	JJ
cord-351517-npcuo1ld	21	30	remission	remission	NN
cord-351517-npcuo1ld	21	31	(	(	-LRB-
cord-351517-npcuo1ld	21	32	28	28	CD
cord-351517-npcuo1ld	21	33	%	%	NN
cord-351517-npcuo1ld	21	34	versus	versus	IN
cord-351517-npcuo1ld	21	35	23	23	CD
cord-351517-npcuo1ld	21	36	%	%	NN
cord-351517-npcuo1ld	21	37	;	;	:
cord-351517-npcuo1ld	21	38	P	p	NN
cord-351517-npcuo1ld	21	39	=	=	SYM
cord-351517-npcuo1ld	21	40	0.10	0.10	CD
cord-351517-npcuo1ld	21	41	)	)	-RRB-
cord-351517-npcuo1ld	21	42	[	[	-LRB-
cord-351517-npcuo1ld	21	43	5	5	CD
cord-351517-npcuo1ld	21	44	]	]	-RRB-
cord-351517-npcuo1ld	21	45	.	.	.
cord-351517-npcuo1ld	22	1	Elsewhere	elsewhere	RB
cord-351517-npcuo1ld	22	2	my	-PRON-	PRP$
cord-351517-npcuo1ld	22	3	colleagues	colleague	NNS
cord-351517-npcuo1ld	22	4	and	and	CC
cord-351517-npcuo1ld	22	5	I	-PRON-	PRP
cord-351517-npcuo1ld	22	6	explain	explain	VBP
cord-351517-npcuo1ld	22	7	this	this	DT
cord-351517-npcuo1ld	22	8	P	p	NN
cord-351517-npcuo1ld	22	9	value	value	NN
cord-351517-npcuo1ld	22	10	does	do	VBZ
cord-351517-npcuo1ld	22	11	not	not	RB
cord-351517-npcuo1ld	22	12	mean	mean	VB
cord-351517-npcuo1ld	22	13	there	there	EX
cord-351517-npcuo1ld	22	14	is	be	VBZ
cord-351517-npcuo1ld	22	15	no	no	DT
cord-351517-npcuo1ld	22	16	difference	difference	NN
cord-351517-npcuo1ld	22	17	in	in	IN
cord-351517-npcuo1ld	22	18	transplant	transplant	NN
cord-351517-npcuo1ld	22	19	rates	rate	NNS
cord-351517-npcuo1ld	22	20	between	between	IN
cord-351517-npcuo1ld	22	21	the	the	DT
cord-351517-npcuo1ld	22	22	arms	arm	NNS
cord-351517-npcuo1ld	22	23	[	[	-LRB-
cord-351517-npcuo1ld	22	24	6	6	CD
cord-351517-npcuo1ld	22	25	,	,	,
cord-351517-npcuo1ld	22	26	7	7	CD
cord-351517-npcuo1ld	22	27	]	]	-RRB-
cord-351517-npcuo1ld	22	28	.	.	.
cord-351517-npcuo1ld	23	1	Rather	rather	RB
cord-351517-npcuo1ld	23	2	,	,	,
cord-351517-npcuo1ld	23	3	this	this	DT
cord-351517-npcuo1ld	23	4	P	p	NN
cord-351517-npcuo1ld	23	5	value	value	NN
cord-351517-npcuo1ld	23	6	means	mean	VBZ
cord-351517-npcuo1ld	23	7	it	-PRON-	PRP
cord-351517-npcuo1ld	23	8	is	be	VBZ
cord-351517-npcuo1ld	23	9	very	very	RB
cord-351517-npcuo1ld	23	10	likely	likely	JJ
cord-351517-npcuo1ld	23	11	transplant	transplant	NN
cord-351517-npcuo1ld	23	12	rates	rate	NNS
cord-351517-npcuo1ld	23	13	are	be	VBP
cord-351517-npcuo1ld	23	14	different	different	JJ
cord-351517-npcuo1ld	23	15	and	and	CC
cord-351517-npcuo1ld	23	16	that	that	IN
cord-351517-npcuo1ld	23	17	the	the	DT
cord-351517-npcuo1ld	23	18	null	null	JJ
cord-351517-npcuo1ld	23	19	hypothesis	hypothesis	NN
cord-351517-npcuo1ld	23	20	is	be	VBZ
cord-351517-npcuo1ld	23	21	simply	simply	RB
cord-351517-npcuo1ld	23	22	not	not	RB
cord-351517-npcuo1ld	23	23	a	a	DT
cord-351517-npcuo1ld	23	24	good	good	JJ
cord-351517-npcuo1ld	23	25	statistical	statistical	JJ
cord-351517-npcuo1ld	23	26	model	model	NN
cord-351517-npcuo1ld	23	27	of	of	IN
cord-351517-npcuo1ld	23	28	these	these	DT
cord-351517-npcuo1ld	23	29	(	(	-LRB-
cord-351517-npcuo1ld	23	30	or	or	CC
cord-351517-npcuo1ld	23	31	more	more	RBR
cord-351517-npcuo1ld	23	32	extreme	extreme	JJ
cord-351517-npcuo1ld	23	33	)	)	-RRB-
cord-351517-npcuo1ld	23	34	data	datum	NNS
cord-351517-npcuo1ld	23	35	.	.	.
cord-351517-npcuo1ld	24	1	More	more	RBR
cord-351517-npcuo1ld	24	2	importantly	importantly	RB
cord-351517-npcuo1ld	24	3	.	.	.
cord-351517-npcuo1ld	25	1	although	although	IN
cord-351517-npcuo1ld	25	2	the	the	DT
cord-351517-npcuo1ld	25	3	trial	trial	NN
cord-351517-npcuo1ld	25	4	reported	report	VBD
cord-351517-npcuo1ld	25	5	a	a	DT
cord-351517-npcuo1ld	25	6	survival	survival	NN
cord-351517-npcuo1ld	25	7	benefit	benefit	NN
cord-351517-npcuo1ld	25	8	of	of	IN
cord-351517-npcuo1ld	25	9	pretransplant	pretransplant	NN
cord-351517-npcuo1ld	25	10	midostaurin	midostaurin	NNP
cord-351517-npcuo1ld	25	11	,	,	,
cord-351517-npcuo1ld	25	12	many	many	JJ
cord-351517-npcuo1ld	25	13	physicians	physician	NNS
cord-351517-npcuo1ld	25	14	fail	fail	VBP
cord-351517-npcuo1ld	25	15	to	to	TO
cord-351517-npcuo1ld	25	16	appreciate	appreciate	VB
cord-351517-npcuo1ld	25	17	midostaurin	midostaurin	NNP
cord-351517-npcuo1ld	25	18	was	be	VBD
cord-351517-npcuo1ld	25	19	stopped	stop	VBN
cord-351517-npcuo1ld	25	20	at	at	IN
cord-351517-npcuo1ld	25	21	the	the	DT
cord-351517-npcuo1ld	25	22	time	time	NN
cord-351517-npcuo1ld	25	23	of	of	IN
cord-351517-npcuo1ld	25	24	transplant	transplant	NN
cord-351517-npcuo1ld	25	25	and	and	CC
cord-351517-npcuo1ld	25	26	that	that	IN
cord-351517-npcuo1ld	25	27	there	there	EX
cord-351517-npcuo1ld	25	28	are	be	VBP
cord-351517-npcuo1ld	25	29	not	not	RB
cord-351517-npcuo1ld	25	30	data	datum	NNS
cord-351517-npcuo1ld	25	31	supporting	support	VBG
cord-351517-npcuo1ld	25	32	giving	give	VBG
cord-351517-npcuo1ld	25	33	midostaurin	midostaurin	NN
cord-351517-npcuo1ld	25	34	after	after	IN
cord-351517-npcuo1ld	25	35	a	a	DT
cord-351517-npcuo1ld	25	36	transplant	transplant	NN
cord-351517-npcuo1ld	25	37	regardless	regardless	RB
cord-351517-npcuo1ld	25	38	of	of	IN
cord-351517-npcuo1ld	25	39	whether	whether	IN
cord-351517-npcuo1ld	25	40	it	-PRON-	PRP
cord-351517-npcuo1ld	25	41	was	be	VBD
cord-351517-npcuo1ld	25	42	given	give	VBN
cord-351517-npcuo1ld	25	43	pretransplant	pretransplant	JJ
cord-351517-npcuo1ld	25	44	.	.	.
cord-351517-npcuo1ld	26	1	Our	-PRON-	PRP$
cord-351517-npcuo1ld	26	2	informal	informal	JJ
cord-351517-npcuo1ld	26	3	survey	survey	NN
cord-351517-npcuo1ld	26	4	indicates	indicate	VBZ
cord-351517-npcuo1ld	26	5	most	most	JJS
cord-351517-npcuo1ld	26	6	transplant	transplant	NN
cord-351517-npcuo1ld	26	7	physicians	physician	NNS
cord-351517-npcuo1ld	26	8	continue	continue	VBP
cord-351517-npcuo1ld	26	9	giving	give	VBG
cord-351517-npcuo1ld	26	10	midostaurin	midostaurin	NNS
cord-351517-npcuo1ld	26	11	despite	despite	IN
cord-351517-npcuo1ld	26	12	this	this	DT
cord-351517-npcuo1ld	26	13	lack	lack	NN
cord-351517-npcuo1ld	26	14	of	of	IN
cord-351517-npcuo1ld	26	15	supporting	support	VBG
cord-351517-npcuo1ld	26	16	data	datum	NNS
cord-351517-npcuo1ld	26	17	.	.	.
cord-351517-npcuo1ld	27	1	Their	-PRON-	PRP$
cord-351517-npcuo1ld	27	2	motto	motto	NN
cord-351517-npcuo1ld	27	3	seems	seem	VBZ
cord-351517-npcuo1ld	27	4	:	:	:
cord-351517-npcuo1ld	27	5	it	-PRON-	PRP
cord-351517-npcuo1ld	27	6	ca	can	MD
cord-351517-npcuo1ld	27	7	n't	not	RB
cord-351517-npcuo1ld	27	8	hurt	hurt	VB
cord-351517-npcuo1ld	27	9	.	.	.
cord-351517-npcuo1ld	28	1	(	(	-LRB-
cord-351517-npcuo1ld	28	2	Sounds	sound	VBZ
cord-351517-npcuo1ld	28	3	like	like	IN
cord-351517-npcuo1ld	28	4	President	President	NNP
cord-351517-npcuo1ld	28	5	Trump	Trump	NNP
cord-351517-npcuo1ld	28	6	promoting	promote	VBG
cord-351517-npcuo1ld	28	7	chloroquine	chloroquine	NN
cord-351517-npcuo1ld	28	8	,	,	,
cord-351517-npcuo1ld	28	9	hydroxychloroquine	hydroxychloroquine	NN
cord-351517-npcuo1ld	28	10	and	and	CC
cord-351517-npcuo1ld	28	11	bleach	bleach	VB
cord-351517-npcuo1ld	28	12	for	for	IN
cord-351517-npcuo1ld	28	13	COVID-19	COVID-19	NNP
cord-351517-npcuo1ld	28	14	.	.	.
cord-351517-npcuo1ld	28	15	)	)	-RRB-
cord-351517-npcuo1ld	29	1	But	but	CC
cord-351517-npcuo1ld	29	2	who	who	WP
cord-351517-npcuo1ld	29	3	knows	know	VBZ
cord-351517-npcuo1ld	29	4	?	?	.
cord-351517-npcuo1ld	30	1	Some	some	DT
cord-351517-npcuo1ld	30	2	data	datum	NNS
cord-351517-npcuo1ld	30	3	suggest	suggest	VBP
cord-351517-npcuo1ld	30	4	one	one	CD
cord-351517-npcuo1ld	30	5	reason	reason	NN
cord-351517-npcuo1ld	30	6	many	many	JJ
cord-351517-npcuo1ld	30	7	new	new	JJ
cord-351517-npcuo1ld	30	8	drugs	drug	NNS
cord-351517-npcuo1ld	30	9	gain	gain	VBP
cord-351517-npcuo1ld	30	10	favour	favour	NN
cord-351517-npcuo1ld	30	11	with	with	IN
cord-351517-npcuo1ld	30	12	physicians	physician	NNS
cord-351517-npcuo1ld	30	13	and	and	CC
cord-351517-npcuo1ld	30	14	patients	patient	NNS
cord-351517-npcuo1ld	30	15	is	be	VBZ
cord-351517-npcuo1ld	30	16	because	because	IN
cord-351517-npcuo1ld	30	17	they	-PRON-	PRP
cord-351517-npcuo1ld	30	18	are	be	VBP
cord-351517-npcuo1ld	30	19	promoted	promote	VBN
cord-351517-npcuo1ld	30	20	by	by	IN
cord-351517-npcuo1ld	30	21	nationally	nationally	RB
cord-351517-npcuo1ld	30	22	or	or	CC
cord-351517-npcuo1ld	30	23	internationally	internationally	RB
cord-351517-npcuo1ld	30	24	by	by	IN
cord-351517-npcuo1ld	30	25	disease	disease	NN
cord-351517-npcuo1ld	30	26	experts	expert	NNS
cord-351517-npcuo1ld	30	27	often	often	RB
cord-351517-npcuo1ld	30	28	referred	refer	VBD
cord-351517-npcuo1ld	30	29	to	to	IN
cord-351517-npcuo1ld	30	30	as	as	IN
cord-351517-npcuo1ld	30	31	key	key	JJ
cord-351517-npcuo1ld	30	32	opinion	opinion	NN
cord-351517-npcuo1ld	30	33	leaders	leader	NNS
cord-351517-npcuo1ld	30	34	(	(	-LRB-
cord-351517-npcuo1ld	30	35	KOLs	KOLs	NNP
cord-351517-npcuo1ld	30	36	)	)	-RRB-
cord-351517-npcuo1ld	30	37	and	and	CC
cord-351517-npcuo1ld	30	38	by	by	IN
cord-351517-npcuo1ld	30	39	drug	drug	NN
cord-351517-npcuo1ld	30	40	companies	company	NNS
cord-351517-npcuo1ld	30	41	,	,	,
cord-351517-npcuo1ld	30	42	often	often	RB
cord-351517-npcuo1ld	30	43	in	in	IN
cord-351517-npcuo1ld	30	44	media	medium	NNS
cord-351517-npcuo1ld	30	45	advertisements	advertisement	NNS
cord-351517-npcuo1ld	30	46	.	.	.
cord-351517-npcuo1ld	31	1	Une	Une	NNP
cord-351517-npcuo1ld	31	2	liaison	liaison	NN
cord-351517-npcuo1ld	31	3	dangerous	dangerous	JJ
cord-351517-npcuo1ld	31	4	?	?	.
cord-351517-npcuo1ld	32	1	This	this	DT
cord-351517-npcuo1ld	32	2	may	may	MD
cord-351517-npcuo1ld	32	3	be	be	VB
cord-351517-npcuo1ld	32	4	so	so	RB
cord-351517-npcuo1ld	32	5	in	in	IN
cord-351517-npcuo1ld	32	6	some	some	DT
cord-351517-npcuo1ld	32	7	instances	instance	NNS
cord-351517-npcuo1ld	32	8	[	[	-LRB-
cord-351517-npcuo1ld	32	9	8	8	CD
cord-351517-npcuo1ld	32	10	]	]	-RRB-
cord-351517-npcuo1ld	32	11	.	.	.
cord-351517-npcuo1ld	33	1	However	however	RB
cord-351517-npcuo1ld	33	2	,	,	,
cord-351517-npcuo1ld	33	3	there	there	EX
cord-351517-npcuo1ld	33	4	are	be	VBP
cord-351517-npcuo1ld	33	5	several	several	JJ
cord-351517-npcuo1ld	33	6	complex	complex	JJ
cord-351517-npcuo1ld	33	7	considerations	consideration	NNS
cord-351517-npcuo1ld	33	8	here	here	RB
cord-351517-npcuo1ld	33	9	.	.	.
cord-351517-npcuo1ld	34	1	KOLs	kol	NNS
cord-351517-npcuo1ld	34	2	are	be	VBP
cord-351517-npcuo1ld	34	3	frequently	frequently	RB
cord-351517-npcuo1ld	34	4	principle	principle	JJ
cord-351517-npcuo1ld	34	5	investigators	investigator	NNS
cord-351517-npcuo1ld	34	6	in	in	IN
cord-351517-npcuo1ld	34	7	the	the	DT
cord-351517-npcuo1ld	34	8	clinical	clinical	JJ
cord-351517-npcuo1ld	34	9	trial(s	trial(s	NNP
cord-351517-npcuo1ld	34	10	)	)	-RRB-
cord-351517-npcuo1ld	34	11	resulting	result	VBG
cord-351517-npcuo1ld	34	12	in	in	IN
cord-351517-npcuo1ld	34	13	a	a	DT
cord-351517-npcuo1ld	34	14	new	new	JJ
cord-351517-npcuo1ld	34	15	drug	drug	NN
cord-351517-npcuo1ld	34	16	approval	approval	NN
cord-351517-npcuo1ld	34	17	.	.	.
cord-351517-npcuo1ld	35	1	Often	often	RB
cord-351517-npcuo1ld	35	2	,	,	,
cord-351517-npcuo1ld	35	3	they	-PRON-	PRP
cord-351517-npcuo1ld	35	4	believe	believe	VBP
cord-351517-npcuo1ld	35	5	,	,	,
cord-351517-npcuo1ld	35	6	sometimes	sometimes	RB
cord-351517-npcuo1ld	35	7	strongly	strongly	RB
cord-351517-npcuo1ld	35	8	or	or	CC
cord-351517-npcuo1ld	35	9	even	even	RB
cord-351517-npcuo1ld	35	10	too	too	RB
cord-351517-npcuo1ld	35	11	strongly	strongly	RB
cord-351517-npcuo1ld	35	12	,	,	,
cord-351517-npcuo1ld	35	13	the	the	DT
cord-351517-npcuo1ld	35	14	new	new	JJ
cord-351517-npcuo1ld	35	15	drug	drug	NN
cord-351517-npcuo1ld	35	16	is	be	VBZ
cord-351517-npcuo1ld	35	17	an	an	DT
cord-351517-npcuo1ld	35	18	important	important	JJ
cord-351517-npcuo1ld	35	19	advance	advance	NN
cord-351517-npcuo1ld	35	20	.	.	.
cord-351517-npcuo1ld	36	1	In	in	IN
cord-351517-npcuo1ld	36	2	psychology	psychology	NN
cord-351517-npcuo1ld	36	3	this	this	DT
cord-351517-npcuo1ld	36	4	process	process	NN
cord-351517-npcuo1ld	36	5	is	be	VBZ
cord-351517-npcuo1ld	36	6	known	know	VBN
cord-351517-npcuo1ld	36	7	as	as	IN
cord-351517-npcuo1ld	36	8	confirmation	confirmation	NN
cord-351517-npcuo1ld	36	9	bias	bias	NN
cord-351517-npcuo1ld	36	10	.	.	.
cord-351517-npcuo1ld	37	1	Having	have	VBG
cord-351517-npcuo1ld	37	2	invested	invest	VBN
cord-351517-npcuo1ld	37	3	several	several	JJ
cord-351517-npcuo1ld	37	4	years	year	NNS
cord-351517-npcuo1ld	37	5	studying	study	VBG
cord-351517-npcuo1ld	37	6	a	a	DT
cord-351517-npcuo1ld	37	7	new	new	JJ
cord-351517-npcuo1ld	37	8	drug	drug	NN
cord-351517-npcuo1ld	37	9	,	,	,
cord-351517-npcuo1ld	37	10	often	often	RB
cord-351517-npcuo1ld	37	11	with	with	IN
cord-351517-npcuo1ld	37	12	considerable	considerable	JJ
cord-351517-npcuo1ld	37	13	effort	effort	NN
cord-351517-npcuo1ld	37	14	and	and	CC
cord-351517-npcuo1ld	37	15	problems	problem	NNS
cord-351517-npcuo1ld	37	16	working	work	VBG
cord-351517-npcuo1ld	37	17	with	with	IN
cord-351517-npcuo1ld	37	18	ethical	ethical	JJ
cord-351517-npcuo1ld	37	19	committees	committee	NNS
cord-351517-npcuo1ld	37	20	,	,	,
cord-351517-npcuo1ld	37	21	clinical	clinical	JJ
cord-351517-npcuo1ld	37	22	research	research	NN
cord-351517-npcuo1ld	37	23	organizations	organization	NNS
cord-351517-npcuo1ld	37	24	(	(	-LRB-
cord-351517-npcuo1ld	37	25	https://www.ashclinicalnews.org/viewpoints/	https://www.ashclinicalnews.org/viewpoints/	NNP
cord-351517-npcuo1ld	37	26	editors	editor	NNS
cord-351517-npcuo1ld	37	27	-	-	HYPH
cord-351517-npcuo1ld	37	28	corner	corner	NN
cord-351517-npcuo1ld	37	29	/	/	SYM
cord-351517-npcuo1ld	37	30	contract	contract	NN
cord-351517-npcuo1ld	37	31	-	-	HYPH
cord-351517-npcuo1ld	37	32	research	research	NN
cord-351517-npcuo1ld	37	33	-	-	HYPH
cord-351517-npcuo1ld	37	34	agonizations/	agonizations/	CD
cord-351517-npcuo1ld	37	35	)	)	-RRB-
cord-351517-npcuo1ld	37	36	;	;	:
cord-351517-npcuo1ld	37	37	sometimes	sometimes	RB
cord-351517-npcuo1ld	37	38	known	know	VBN
cord-351517-npcuo1ld	37	39	as	as	IN
cord-351517-npcuo1ld	37	40	clinical	clinical	JJ
cord-351517-npcuo1ld	37	41	research	research	NN
cord-351517-npcuo1ld	37	42	aggravations	aggravation	NNS
cord-351517-npcuo1ld	37	43	)	)	-RRB-
cord-351517-npcuo1ld	37	44	,	,	,
cord-351517-npcuo1ld	37	45	drug	drug	NN
cord-351517-npcuo1ld	37	46	company	company	NN
cord-351517-npcuo1ld	37	47	study	study	NN
cord-351517-npcuo1ld	37	48	managers	manager	NNS
cord-351517-npcuo1ld	37	49	etc	etc	FW
cord-351517-npcuo1ld	37	50	.	.	.
cord-351517-npcuo1ld	38	1	people	people	NNS
cord-351517-npcuo1ld	38	2	want	want	VBP
cord-351517-npcuo1ld	38	3	to	to	TO
cord-351517-npcuo1ld	38	4	believe	believe	VB
cord-351517-npcuo1ld	38	5	their	-PRON-	PRP$
cord-351517-npcuo1ld	38	6	effort	effort	NN
cord-351517-npcuo1ld	38	7	worthwhile	worthwhile	JJ
cord-351517-npcuo1ld	38	8	.	.	.
cord-351517-npcuo1ld	39	1	Otherwise	otherwise	RB
cord-351517-npcuo1ld	39	2	one	one	PRP
cord-351517-npcuo1ld	39	3	would	would	MD
cord-351517-npcuo1ld	39	4	seem	seem	VB
cord-351517-npcuo1ld	39	5	to	to	TO
cord-351517-npcuo1ld	39	6	have	have	VB
cord-351517-npcuo1ld	39	7	wasted	waste	VBN
cord-351517-npcuo1ld	39	8	their	-PRON-	PRP$
cord-351517-npcuo1ld	39	9	time	time	NN
cord-351517-npcuo1ld	39	10	,	,	,
cord-351517-npcuo1ld	39	11	energy	energy	NN
cord-351517-npcuo1ld	39	12	and	and	CC
cord-351517-npcuo1ld	39	13	perhaps	perhaps	RB
cord-351517-npcuo1ld	39	14	destroyed	destroy	VBN
cord-351517-npcuo1ld	39	15	your	-PRON-	PRP$
cord-351517-npcuo1ld	39	16	marriage	marriage	NN
cord-351517-npcuo1ld	39	17	,	,	,
cord-351517-npcuo1ld	39	18	missed	miss	VBD
cord-351517-npcuo1ld	39	19	your	-PRON-	PRP$
cord-351517-npcuo1ld	39	20	children	child	NNS
cord-351517-npcuo1ld	39	21	growing	grow	VBG
cord-351517-npcuo1ld	39	22	up	up	RP
cord-351517-npcuo1ld	39	23	,	,	,
cord-351517-npcuo1ld	39	24	both	both	DT
cord-351517-npcuo1ld	39	25	or	or	CC
cord-351517-npcuo1ld	39	26	perhaps	perhaps	RB
cord-351517-npcuo1ld	39	27	something	something	NN
cord-351517-npcuo1ld	39	28	even	even	RB
cord-351517-npcuo1ld	39	29	worse	worse	RBR
cord-351517-npcuo1ld	39	30	(	(	-LRB-
cord-351517-npcuo1ld	39	31	a	a	DT
cord-351517-npcuo1ld	39	32	fling	fling	NN
cord-351517-npcuo1ld	39	33	in	in	IN
cord-351517-npcuo1ld	39	34	Cancun	Cancun	NNP
cord-351517-npcuo1ld	39	35	?	?	.
cord-351517-npcuo1ld	39	36	)	)	-RRB-
cord-351517-npcuo1ld	39	37	.	.	.
cord-351517-npcuo1ld	40	1	But	but	CC
cord-351517-npcuo1ld	40	2	we	-PRON-	PRP
cord-351517-npcuo1ld	40	3	need	need	VBP
cord-351517-npcuo1ld	40	4	to	to	TO
cord-351517-npcuo1ld	40	5	acknowledge	acknowledge	VB
cord-351517-npcuo1ld	40	6	other	other	JJ
cord-351517-npcuo1ld	40	7	considerations	consideration	NNS
cord-351517-npcuo1ld	40	8	such	such	JJ
cord-351517-npcuo1ld	40	9	as	as	IN
cord-351517-npcuo1ld	40	10	the	the	DT
cord-351517-npcuo1ld	40	11	requirement	requirement	NN
cord-351517-npcuo1ld	40	12	to	to	TO
cord-351517-npcuo1ld	40	13	publish	publish	VB
cord-351517-npcuo1ld	40	14	for	for	IN
cord-351517-npcuo1ld	40	15	academic	academic	JJ
cord-351517-npcuo1ld	40	16	promotion	promotion	NN
cord-351517-npcuo1ld	40	17	and	and	CC
cord-351517-npcuo1ld	40	18	advancement	advancement	NN
cord-351517-npcuo1ld	40	19	.	.	.
cord-351517-npcuo1ld	41	1	It	-PRON-	PRP
cord-351517-npcuo1ld	41	2	is	be	VBZ
cord-351517-npcuo1ld	41	3	far	far	RB
cord-351517-npcuo1ld	41	4	easier	easy	JJR
cord-351517-npcuo1ld	41	5	to	to	TO
cord-351517-npcuo1ld	41	6	publish	publish	VB
cord-351517-npcuo1ld	41	7	a	a	DT
cord-351517-npcuo1ld	41	8	study	study	NN
cord-351517-npcuo1ld	41	9	claiming	claim	VBG
cord-351517-npcuo1ld	41	10	a	a	DT
cord-351517-npcuo1ld	41	11	new	new	JJ
cord-351517-npcuo1ld	41	12	,	,	,
cord-351517-npcuo1ld	41	13	typically	typically	RB
cord-351517-npcuo1ld	41	14	more	more	RBR
cord-351517-npcuo1ld	41	15	expensive	expensive	JJ
cord-351517-npcuo1ld	41	16	drug	drug	NN
cord-351517-npcuo1ld	41	17	is	be	VBZ
cord-351517-npcuo1ld	41	18	better	well	JJR
cord-351517-npcuo1ld	41	19	than	than	IN
cord-351517-npcuo1ld	41	20	an	an	DT
cord-351517-npcuo1ld	41	21	old	old	JJ
cord-351517-npcuo1ld	41	22	,	,	,
cord-351517-npcuo1ld	41	23	typically	typically	RB
cord-351517-npcuo1ld	41	24	cheaper	cheap	JJR
cord-351517-npcuo1ld	41	25	drug	drug	NN
cord-351517-npcuo1ld	41	26	than	than	IN
cord-351517-npcuo1ld	41	27	the	the	DT
cord-351517-npcuo1ld	41	28	converse	converse	NN
cord-351517-npcuo1ld	41	29	.	.	.
cord-351517-npcuo1ld	42	1	And	and	CC
cord-351517-npcuo1ld	42	2	there	there	EX
cord-351517-npcuo1ld	42	3	are	be	VBP
cord-351517-npcuo1ld	42	4	also	also	RB
cord-351517-npcuo1ld	42	5	some	some	DT
cord-351517-npcuo1ld	42	6	less	less	RBR
cord-351517-npcuo1ld	42	7	altruistic	altruistic	JJ
cord-351517-npcuo1ld	42	8	considerations	consideration	NNS
cord-351517-npcuo1ld	42	9	.	.	.
cord-351517-npcuo1ld	43	1	Everyone	everyone	NN
cord-351517-npcuo1ld	43	2	likes	like	VBZ
cord-351517-npcuo1ld	43	3	to	to	TO
cord-351517-npcuo1ld	43	4	address	address	VB
cord-351517-npcuo1ld	43	5	a	a	DT
cord-351517-npcuo1ld	43	6	large	large	JJ
cord-351517-npcuo1ld	43	7	,	,	,
cord-351517-npcuo1ld	43	8	admiring	admire	VBG
cord-351517-npcuo1ld	43	9	audience	audience	NN
cord-351517-npcuo1ld	43	10	,	,	,
cord-351517-npcuo1ld	43	11	have	have	VB
cord-351517-npcuo1ld	43	12	your	-PRON-	PRP$
cord-351517-npcuo1ld	43	13	headshot	headshot	NN
cord-351517-npcuo1ld	43	14	(	(	-LRB-
cord-351517-npcuo1ld	43	15	typically	typically	RB
cord-351517-npcuo1ld	43	16	of	of	IN
cord-351517-npcuo1ld	43	17	you	-PRON-	PRP
cord-351517-npcuo1ld	43	18	20	20	CD
cord-351517-npcuo1ld	43	19	years	year	NNS
cord-351517-npcuo1ld	43	20	ago	ago	RB
cord-351517-npcuo1ld	43	21	)	)	-RRB-
cord-351517-npcuo1ld	43	22	projected	project	VBD
cord-351517-npcuo1ld	43	23	on	on	IN
cord-351517-npcuo1ld	43	24	a	a	DT
cord-351517-npcuo1ld	43	25	huge	huge	JJ
cord-351517-npcuo1ld	43	26	screen	screen	NN
cord-351517-npcuo1ld	43	27	,	,	,
cord-351517-npcuo1ld	43	28	travel	travel	VBP
cord-351517-npcuo1ld	43	29	abroad	abroad	RB
cord-351517-npcuo1ld	43	30	,	,	,
cord-351517-npcuo1ld	43	31	be	be	VB
cord-351517-npcuo1ld	43	32	feted	fete	VBN
cord-351517-npcuo1ld	43	33	at	at	IN
cord-351517-npcuo1ld	43	34	a	a	DT
cord-351517-npcuo1ld	43	35	reception	reception	NN
cord-351517-npcuo1ld	43	36	and	and	CC
cord-351517-npcuo1ld	43	37	dine	dine	VB
cord-351517-npcuo1ld	43	38	in	in	IN
cord-351517-npcuo1ld	43	39	Le	Le	NNP
cord-351517-npcuo1ld	43	40	Bernadine	Bernadine	NNP
cord-351517-npcuo1ld	43	41	in	in	IN
cord-351517-npcuo1ld	43	42	New	New	NNP
cord-351517-npcuo1ld	43	43	York	York	NNP
cord-351517-npcuo1ld	43	44	,	,	,
cord-351517-npcuo1ld	43	45	The	the	DT
cord-351517-npcuo1ld	43	46	Ivy	Ivy	NNP
cord-351517-npcuo1ld	43	47	in	in	IN
cord-351517-npcuo1ld	43	48	London	London	NNP
cord-351517-npcuo1ld	43	49	or	or	CC
cord-351517-npcuo1ld	43	50	La	La	NNP
cord-351517-npcuo1ld	43	51	Tour	Tour	NNP
cord-351517-npcuo1ld	43	52	d'Argent	d'Argent	NNP
cord-351517-npcuo1ld	43	53	in	in	IN
cord-351517-npcuo1ld	43	54	Paris	Paris	NNP
cord-351517-npcuo1ld	43	55	.	.	.
cord-351517-npcuo1ld	44	1	This	this	DT
cord-351517-npcuo1ld	44	2	behavior	behavior	NN
cord-351517-npcuo1ld	44	3	is	be	VBZ
cord-351517-npcuo1ld	44	4	human	human	JJ
cord-351517-npcuo1ld	44	5	nature	nature	NN
cord-351517-npcuo1ld	44	6	and	and	CC
cord-351517-npcuo1ld	44	7	we	-PRON-	PRP
cord-351517-npcuo1ld	44	8	can	can	MD
cord-351517-npcuo1ld	44	9	not	not	RB
cord-351517-npcuo1ld	44	10	unfairly	unfairly	RB
cord-351517-npcuo1ld	44	11	fault	fault	VB
cord-351517-npcuo1ld	44	12	them	-PRON-	PRP
cord-351517-npcuo1ld	44	13	.	.	.
cord-351517-npcuo1ld	45	1	Generic	generic	JJ
cord-351517-npcuo1ld	45	2	drug	drug	NN
cord-351517-npcuo1ld	45	3	makers	maker	NNS
cord-351517-npcuo1ld	45	4	are	be	VBP
cord-351517-npcuo1ld	45	5	likely	likely	JJ
cord-351517-npcuo1ld	45	6	to	to	TO
cord-351517-npcuo1ld	45	7	take	take	VB
cord-351517-npcuo1ld	45	8	you	-PRON-	PRP
cord-351517-npcuo1ld	45	9	and	and	CC
cord-351517-npcuo1ld	45	10	the	the	DT
cord-351517-npcuo1ld	45	11	meeting	meeting	NN
cord-351517-npcuo1ld	45	12	organizers	organizer	NNS
cord-351517-npcuo1ld	45	13	to	to	IN
cord-351517-npcuo1ld	45	14	Nathan	Nathan	NNP
cord-351517-npcuo1ld	45	15	's	's	POS
cord-351517-npcuo1ld	45	16	Famous	Famous	NNP
cord-351517-npcuo1ld	45	17	Hot	Hot	NNP
cord-351517-npcuo1ld	45	18	Dogs	Dogs	NNP
cord-351517-npcuo1ld	45	19	in	in	IN
cord-351517-npcuo1ld	45	20	Coney	Coney	NNP
cord-351517-npcuo1ld	45	21	Island	Island	NNP
cord-351517-npcuo1ld	45	22	for	for	IN
cord-351517-npcuo1ld	45	23	dinner	dinner	NN
cord-351517-npcuo1ld	45	24	(	(	-LRB-
cord-351517-npcuo1ld	45	25	excellent	excellent	JJ
cord-351517-npcuo1ld	45	26	but	but	CC
cord-351517-npcuo1ld	45	27	expensive	expensive	JJ
cord-351517-npcuo1ld	45	28	;	;	:
cord-351517-npcuo1ld	45	29	currently	currently	RB
cord-351517-npcuo1ld	45	30	$	$	$
cord-351517-npcuo1ld	45	31	7.99	7.99	CD
cord-351517-npcuo1ld	45	32	USD	usd	NN
cord-351517-npcuo1ld	45	33	;	;	:
cord-351517-npcuo1ld	45	34	2	2	CD
cord-351517-npcuo1ld	45	35	for	for	IN
cord-351517-npcuo1ld	45	36	$	$	$
cord-351517-npcuo1ld	45	37	15.00	15.00	CD
cord-351517-npcuo1ld	45	38	)	)	-RRB-
cord-351517-npcuo1ld	45	39	,	,	,
cord-351517-npcuo1ld	45	40	no	no	DT
cord-351517-npcuo1ld	45	41	fries	fry	NNS
cord-351517-npcuo1ld	45	42	or	or	CC
cord-351517-npcuo1ld	45	43	,	,	,
cord-351517-npcuo1ld	45	44	for	for	IN
cord-351517-npcuo1ld	45	45	Europeans	Europeans	NNPS
cord-351517-npcuo1ld	45	46	,	,	,
cord-351517-npcuo1ld	45	47	traditional	traditional	JJ
cord-351517-npcuo1ld	45	48	pie	pie	NN
cord-351517-npcuo1ld	45	49	'	'	CC
cord-351517-npcuo1ld	45	50	n	n	CC
cord-351517-npcuo1ld	45	51	'	'	CC
cord-351517-npcuo1ld	45	52	mash	mash	NN
cord-351517-npcuo1ld	45	53	with	with	IN
cord-351517-npcuo1ld	45	54	eels	eel	NNS
cord-351517-npcuo1ld	45	55	at	at	IN
cord-351517-npcuo1ld	45	56	Cockney	Cockney	NNP
cord-351517-npcuo1ld	45	57	's	's	POS
cord-351517-npcuo1ld	45	58	at	at	IN
cord-351517-npcuo1ld	45	59	314	314	CD
cord-351517-npcuo1ld	45	60	Portobello	Portobello	NNP
cord-351517-npcuo1ld	45	61	Road	Road	NNP
cord-351517-npcuo1ld	45	62	,	,	,
cord-351517-npcuo1ld	45	63	London	London	NNP
cord-351517-npcuo1ld	45	64	W10	W10	NNP
cord-351517-npcuo1ld	45	65	5RU	5RU	NNP
cord-351517-npcuo1ld	45	66	(	(	-LRB-
cord-351517-npcuo1ld	45	67	£	£	$
cord-351517-npcuo1ld	45	68	7	7	CD
cord-351517-npcuo1ld	45	69	)	)	-RRB-
cord-351517-npcuo1ld	45	70	.	.	.
cord-351517-npcuo1ld	46	1	Everyone	everyone	NN
cord-351517-npcuo1ld	46	2	likes	like	VBZ
cord-351517-npcuo1ld	46	3	to	to	TO
cord-351517-npcuo1ld	46	4	be	be	VB
cord-351517-npcuo1ld	46	5	liked	like	VBN
cord-351517-npcuo1ld	46	6	.	.	.
cord-351517-npcuo1ld	47	1	In	in	IN
cord-351517-npcuo1ld	47	2	contrast	contrast	NN
cord-351517-npcuo1ld	47	3	,	,	,
cord-351517-npcuo1ld	47	4	consider	consider	VB
cord-351517-npcuo1ld	47	5	a	a	DT
cord-351517-npcuo1ld	47	6	world	world	NN
cord-351517-npcuo1ld	47	7	where	where	WRB
cord-351517-npcuo1ld	47	8	drug	drug	NN
cord-351517-npcuo1ld	47	9	companies	company	NNS
cord-351517-npcuo1ld	47	10	do	do	VBP
cord-351517-npcuo1ld	47	11	not	not	RB
cord-351517-npcuo1ld	47	12	develop	develop	VB
cord-351517-npcuo1ld	47	13	new	new	JJ
cord-351517-npcuo1ld	47	14	drugs	drug	NNS
cord-351517-npcuo1ld	47	15	for	for	IN
cord-351517-npcuo1ld	47	16	the	the	DT
cord-351517-npcuo1ld	47	17	diseases	disease	NNS
cord-351517-npcuo1ld	47	18	we	-PRON-	PRP
cord-351517-npcuo1ld	47	19	need	need	VBP
cord-351517-npcuo1ld	47	20	to	to	TO
cord-351517-npcuo1ld	47	21	treat	treat	VB
cord-351517-npcuo1ld	47	22	.	.	.
cord-351517-npcuo1ld	48	1	First	first	RB
cord-351517-npcuo1ld	48	2	,	,	,
cord-351517-npcuo1ld	48	3	we	-PRON-	PRP
cord-351517-npcuo1ld	48	4	would	would	MD
cord-351517-npcuo1ld	48	5	be	be	VB
cord-351517-npcuo1ld	48	6	left	leave	VBN
cord-351517-npcuo1ld	48	7	with	with	IN
cord-351517-npcuo1ld	48	8	methotrexate	methotrexate	NNP
cord-351517-npcuo1ld	48	9	and	and	CC
cord-351517-npcuo1ld	48	10	corticosteroids	corticosteroid	NNS
cord-351517-npcuo1ld	48	11	to	to	TO
cord-351517-npcuo1ld	48	12	prevent	prevent	VB
cord-351517-npcuo1ld	48	13	or	or	CC
cord-351517-npcuo1ld	48	14	treat	treat	VB
cord-351517-npcuo1ld	48	15	GvHD	GvHD	NNP
cord-351517-npcuo1ld	48	16	.	.	.
cord-351517-npcuo1ld	49	1	Almost	almost	RB
cord-351517-npcuo1ld	49	2	all	all	DT
cord-351517-npcuo1ld	49	3	new	new	JJ
cord-351517-npcuo1ld	49	4	drugs	drug	NNS
cord-351517-npcuo1ld	49	5	we	-PRON-	PRP
cord-351517-npcuo1ld	49	6	use	use	VBP
cord-351517-npcuo1ld	49	7	in	in	IN
cord-351517-npcuo1ld	49	8	the	the	DT
cord-351517-npcuo1ld	49	9	past	past	JJ
cord-351517-npcuo1ld	49	10	30	30	CD
cord-351517-npcuo1ld	49	11	years	year	NNS
cord-351517-npcuo1ld	49	12	have	have	VBP
cord-351517-npcuo1ld	49	13	come	come	VBN
cord-351517-npcuo1ld	49	14	from	from	IN
cord-351517-npcuo1ld	49	15	drug	drug	NN
cord-351517-npcuo1ld	49	16	companies	company	NNS
cord-351517-npcuo1ld	49	17	,	,	,
cord-351517-npcuo1ld	49	18	not	not	RB
cord-351517-npcuo1ld	49	19	academia	academia	NN
cord-351517-npcuo1ld	49	20	.	.	.
cord-351517-npcuo1ld	50	1	But	but	CC
cord-351517-npcuo1ld	50	2	there	there	EX
cord-351517-npcuo1ld	50	3	are	be	VBP
cord-351517-npcuo1ld	50	4	other	other	JJ
cord-351517-npcuo1ld	50	5	far	far	RB
cord-351517-npcuo1ld	50	6	-	-	HYPH
cord-351517-npcuo1ld	50	7	reaching	reach	VBG
cord-351517-npcuo1ld	50	8	implications	implication	NNS
cord-351517-npcuo1ld	50	9	.	.	.
cord-351517-npcuo1ld	51	1	For	for	IN
cord-351517-npcuo1ld	51	2	example	example	NN
cord-351517-npcuo1ld	51	3	,	,	,
cord-351517-npcuo1ld	51	4	annual	annual	JJ
cord-351517-npcuo1ld	51	5	educational	educational	JJ
cord-351517-npcuo1ld	51	6	meetings	meeting	NNS
cord-351517-npcuo1ld	51	7	such	such	JJ
cord-351517-npcuo1ld	51	8	as	as	IN
cord-351517-npcuo1ld	51	9	those	those	DT
cord-351517-npcuo1ld	51	10	of	of	IN
cord-351517-npcuo1ld	51	11	the	the	DT
cord-351517-npcuo1ld	51	12	recent	recent	JJ
cord-351517-npcuo1ld	51	13	Transplantation	Transplantation	NNP
cord-351517-npcuo1ld	51	14	and	and	CC
cord-351517-npcuo1ld	51	15	Cellular	Cellular	NNP
cord-351517-npcuo1ld	51	16	Therapy	Therapy	NNP
cord-351517-npcuo1ld	51	17	(	(	-LRB-
cord-351517-npcuo1ld	51	18	TCT	TCT	NNP
cord-351517-npcuo1ld	51	19	)	)	-RRB-
cord-351517-npcuo1ld	51	20	meeting	meeting	NN
cord-351517-npcuo1ld	51	21	in	in	IN
cord-351517-npcuo1ld	51	22	Orlando	Orlando	NNP
cord-351517-npcuo1ld	51	23	and	and	CC
cord-351517-npcuo1ld	51	24	the	the	DT
cord-351517-npcuo1ld	51	25	European	European	NNP
cord-351517-npcuo1ld	51	26	Bone	Bone	NNP
cord-351517-npcuo1ld	51	27	Marrow	Marrow	NNP
cord-351517-npcuo1ld	51	28	Transplant	Transplant	NNP
cord-351517-npcuo1ld	51	29	Group	Group	NNP
cord-351517-npcuo1ld	51	30	(	(	-LRB-
cord-351517-npcuo1ld	51	31	EBMT	EBMT	NNP
cord-351517-npcuo1ld	51	32	)	)	-RRB-
cord-351517-npcuo1ld	52	1	Meeting	meet	VBG
cord-351517-npcuo1ld	52	2	in	in	IN
cord-351517-npcuo1ld	52	3	Frankfurt	Frankfurt	NNP
cord-351517-npcuo1ld	52	4	would	would	MD
cord-351517-npcuo1ld	52	5	have	have	VB
cord-351517-npcuo1ld	52	6	2000	2000	CD
cord-351517-npcuo1ld	52	7	rather	rather	RB
cord-351517-npcuo1ld	52	8	than	than	IN
cord-351517-npcuo1ld	52	9	3000	3000	CD
cord-351517-npcuo1ld	52	10	attendees	attendee	NNS
cord-351517-npcuo1ld	52	11	.	.	.
cord-351517-npcuo1ld	53	1	About	about	IN
cord-351517-npcuo1ld	53	2	onethird	onethird	NN
cord-351517-npcuo1ld	53	3	of	of	IN
cord-351517-npcuo1ld	53	4	the	the	DT
cord-351517-npcuo1ld	53	5	attendees	attendee	NNS
cord-351517-npcuo1ld	53	6	are	be	VBP
cord-351517-npcuo1ld	53	7	drug	drug	NN
cord-351517-npcuo1ld	53	8	company	company	NN
cord-351517-npcuo1ld	53	9	employees	employee	NNS
cord-351517-npcuo1ld	53	10	or	or	CC
cord-351517-npcuo1ld	53	11	physicians	physician	NNS
cord-351517-npcuo1ld	53	12	sponsored	sponsor	VBN
cord-351517-npcuo1ld	53	13	to	to	TO
cord-351517-npcuo1ld	53	14	attend	attend	VB
cord-351517-npcuo1ld	53	15	the	the	DT
cord-351517-npcuo1ld	53	16	meeting	meeting	NN
cord-351517-npcuo1ld	53	17	by	by	IN
cord-351517-npcuo1ld	53	18	drug	drug	NN
cord-351517-npcuo1ld	53	19	companies	company	NNS
cord-351517-npcuo1ld	53	20	.	.	.
cord-351517-npcuo1ld	54	1	Much	much	JJ
cord-351517-npcuo1ld	54	2	of	of	IN
cord-351517-npcuo1ld	54	3	the	the	DT
cord-351517-npcuo1ld	54	4	funding	funding	NN
cord-351517-npcuo1ld	54	5	for	for	IN
cord-351517-npcuo1ld	54	6	these	these	DT
cord-351517-npcuo1ld	54	7	annual	annual	JJ
cord-351517-npcuo1ld	54	8	meetings	meeting	NNS
cord-351517-npcuo1ld	54	9	comes	come	VBZ
cord-351517-npcuo1ld	54	10	from	from	IN
cord-351517-npcuo1ld	54	11	the	the	DT
cord-351517-npcuo1ld	54	12	drug	drug	NN
cord-351517-npcuo1ld	54	13	industry	industry	NN
cord-351517-npcuo1ld	54	14	,	,	,
cord-351517-npcuo1ld	54	15	not	not	RB
cord-351517-npcuo1ld	54	16	registration	registration	NN
cord-351517-npcuo1ld	54	17	fees	fee	NNS
cord-351517-npcuo1ld	54	18	.	.	.
cord-351517-npcuo1ld	55	1	TCT	TCT	NNP
cord-351517-npcuo1ld	55	2	and	and	CC
cord-351517-npcuo1ld	55	3	EBMT	EBMT	NNP
cord-351517-npcuo1ld	55	4	charge	charge	NN
cord-351517-npcuo1ld	55	5	drug	drug	NN
cord-351517-npcuo1ld	55	6	companies	company	NNS
cord-351517-npcuo1ld	55	7	substantial	substantial	JJ
cord-351517-npcuo1ld	55	8	monies	monie	NNS
cord-351517-npcuo1ld	55	9	for	for	IN
cord-351517-npcuo1ld	55	10	exhibition	exhibition	NN
cord-351517-npcuo1ld	55	11	space	space	NN
cord-351517-npcuo1ld	55	12	and	and	CC
cord-351517-npcuo1ld	55	13	for	for	IN
cord-351517-npcuo1ld	55	14	the	the	DT
cord-351517-npcuo1ld	55	15	opportunity	opportunity	NN
cord-351517-npcuo1ld	55	16	to	to	TO
cord-351517-npcuo1ld	55	17	present	present	VB
cord-351517-npcuo1ld	55	18	their	-PRON-	PRP$
cord-351517-npcuo1ld	55	19	new	new	JJ
cord-351517-npcuo1ld	55	20	drugs	drug	NNS
cord-351517-npcuo1ld	55	21	in	in	IN
cord-351517-npcuo1ld	55	22	so	so	RB
cord-351517-npcuo1ld	55	23	-	-	HYPH
cord-351517-npcuo1ld	55	24	called	call	VBN
cord-351517-npcuo1ld	55	25	product	product	NN
cord-351517-npcuo1ld	55	26	theatres	theatre	NNS
cord-351517-npcuo1ld	55	27	.	.	.
cord-351517-npcuo1ld	56	1	Imagine	imagine	VB
cord-351517-npcuo1ld	56	2	an	an	DT
cord-351517-npcuo1ld	56	3	exhibition	exhibition	NN
cord-351517-npcuo1ld	56	4	space	space	NN
cord-351517-npcuo1ld	56	5	at	at	IN
cord-351517-npcuo1ld	56	6	one	one	CD
cord-351517-npcuo1ld	56	7	of	of	IN
cord-351517-npcuo1ld	56	8	these	these	DT
cord-351517-npcuo1ld	56	9	meetings	meeting	NNS
cord-351517-npcuo1ld	56	10	without	without	IN
cord-351517-npcuo1ld	56	11	drug	drug	NN
cord-351517-npcuo1ld	56	12	company	company	NN
cord-351517-npcuo1ld	56	13	booths	booth	NNS
cord-351517-npcuo1ld	56	14	.	.	.
cord-351517-npcuo1ld	57	1	It	-PRON-	PRP
cord-351517-npcuo1ld	57	2	would	would	MD
cord-351517-npcuo1ld	57	3	look	look	VB
cord-351517-npcuo1ld	57	4	like	like	IN
cord-351517-npcuo1ld	57	5	Grand	Grand	NNP
cord-351517-npcuo1ld	57	6	Central	Central	NNP
cord-351517-npcuo1ld	57	7	Terminal	Terminal	NNP
cord-351517-npcuo1ld	57	8	devoid	devoid	NN
cord-351517-npcuo1ld	57	9	of	of	IN
cord-351517-npcuo1ld	57	10	people	people	NNS
cord-351517-npcuo1ld	57	11	with	with	IN
cord-351517-npcuo1ld	57	12	only	only	RB
cord-351517-npcuo1ld	57	13	the	the	DT
cord-351517-npcuo1ld	57	14	central	central	JJ
cord-351517-npcuo1ld	57	15	lonely	lonely	JJ
cord-351517-npcuo1ld	57	16	information	information	NN
cord-351517-npcuo1ld	57	17	kiosk	kiosk	NN
cord-351517-npcuo1ld	57	18	.	.	.
cord-351517-npcuo1ld	58	1	A	a	DT
cord-351517-npcuo1ld	58	2	world	world	NN
cord-351517-npcuo1ld	58	3	without	without	IN
cord-351517-npcuo1ld	58	4	free	free	JJ
cord-351517-npcuo1ld	58	5	cappuccino	cappuccino	NN
cord-351517-npcuo1ld	58	6	or	or	CC
cord-351517-npcuo1ld	58	7	frozen	frozen	JJ
cord-351517-npcuo1ld	58	8	yogurt	yogurt	NN
cord-351517-npcuo1ld	58	9	,	,	,
cord-351517-npcuo1ld	58	10	video	video	NN
cord-351517-npcuo1ld	58	11	games	game	NNS
cord-351517-npcuo1ld	58	12	,	,	,
cord-351517-npcuo1ld	58	13	giveaways	giveaway	NNS
cord-351517-npcuo1ld	58	14	for	for	IN
cord-351517-npcuo1ld	58	15	which	which	WDT
cord-351517-npcuo1ld	58	16	physicians	physician	NNS
cord-351517-npcuo1ld	58	17	earning	earn	VBG
cord-351517-npcuo1ld	58	18	>	>	XX
cord-351517-npcuo1ld	58	19	$	$	$
cord-351517-npcuo1ld	58	20	300,000	300,000	CD
cord-351517-npcuo1ld	58	21	per	per	IN
cord-351517-npcuo1ld	58	22	year	year	NN
cord-351517-npcuo1ld	58	23	are	be	VBP
cord-351517-npcuo1ld	58	24	willing	willing	JJ
cord-351517-npcuo1ld	58	25	to	to	TO
cord-351517-npcuo1ld	58	26	que	que	VB
cord-351517-npcuo1ld	58	27	for	for	IN
cord-351517-npcuo1ld	58	28	15	15	CD
cord-351517-npcuo1ld	58	29	min	min	NN
cord-351517-npcuo1ld	58	30	.	.	.
cord-351517-npcuo1ld	59	1	Amazing	amazing	JJ
cord-351517-npcuo1ld	59	2	.	.	.
cord-351517-npcuo1ld	60	1	BLOOD	blood	NN
cord-351517-npcuo1ld	60	2	AND	and	CC
cord-351517-npcuo1ld	60	3	MARROW	marrow	NN
cord-351517-npcuo1ld	60	4	TRANS	TRANS	NNP
cord-351517-npcuo1ld	60	5	-	-	HYPH
cord-351517-npcuo1ld	60	6	PLANTATION	PLANTATION	NNP
cord-351517-npcuo1ld	60	7	is	be	VBZ
cord-351517-npcuo1ld	60	8	filled	fill	VBN
cord-351517-npcuo1ld	60	9	with	with	IN
cord-351517-npcuo1ld	60	10	advertisements	advertisement	NNS
cord-351517-npcuo1ld	60	11	for	for	IN
cord-351517-npcuo1ld	60	12	new	new	JJ
cord-351517-npcuo1ld	60	13	drugs	drug	NNS
cord-351517-npcuo1ld	60	14	.	.	.
cord-351517-npcuo1ld	61	1	I	-PRON-	PRP
cord-351517-npcuo1ld	61	2	doubt	doubt	VBP
cord-351517-npcuo1ld	61	3	many	many	JJ
cord-351517-npcuo1ld	61	4	journals	journal	NNS
cord-351517-npcuo1ld	61	5	would	would	MD
cord-351517-npcuo1ld	61	6	be	be	VB
cord-351517-npcuo1ld	61	7	able	able	JJ
cord-351517-npcuo1ld	61	8	to	to	TO
cord-351517-npcuo1ld	61	9	achieve	achieve	VB
cord-351517-npcuo1ld	61	10	widespread	widespread	JJ
cord-351517-npcuo1ld	61	11	distribution	distribution	NN
cord-351517-npcuo1ld	61	12	at	at	IN
cord-351517-npcuo1ld	61	13	a	a	DT
cord-351517-npcuo1ld	61	14	reasonable	reasonable	JJ
cord-351517-npcuo1ld	61	15	cost	cost	NN
cord-351517-npcuo1ld	61	16	to	to	IN
cord-351517-npcuo1ld	61	17	society	society	NN
cord-351517-npcuo1ld	61	18	members	member	NNS
cord-351517-npcuo1ld	61	19	without	without	IN
cord-351517-npcuo1ld	61	20	advertising	advertising	NN
cord-351517-npcuo1ld	61	21	income	income	NN
cord-351517-npcuo1ld	61	22	.	.	.
cord-351517-npcuo1ld	62	1	Likewise	likewise	RB
cord-351517-npcuo1ld	62	2	,	,	,
cord-351517-npcuo1ld	62	3	their	-PRON-	PRP$
cord-351517-npcuo1ld	62	4	websites	website	NNS
cord-351517-npcuo1ld	62	5	are	be	VBP
cord-351517-npcuo1ld	62	6	where	where	WRB
cord-351517-npcuo1ld	62	7	you	-PRON-	PRP
cord-351517-npcuo1ld	62	8	are	be	VBP
cord-351517-npcuo1ld	62	9	bombarded	bombard	VBN
cord-351517-npcuo1ld	62	10	by	by	IN
cord-351517-npcuo1ld	62	11	unsolicited	unsolicited	JJ
cord-351517-npcuo1ld	62	12	advertisements	advertisement	NNS
cord-351517-npcuo1ld	62	13	for	for	IN
cord-351517-npcuo1ld	62	14	new	new	JJ
cord-351517-npcuo1ld	62	15	transplant	transplant	NN
cord-351517-npcuo1ld	62	16	-	-	HYPH
cord-351517-npcuo1ld	62	17	related	relate	VBN
cord-351517-npcuo1ld	62	18	drugs	drug	NNS
cord-351517-npcuo1ld	62	19	.	.	.
cord-351517-npcuo1ld	63	1	And	and	CC
cord-351517-npcuo1ld	63	2	think	think	VB
cord-351517-npcuo1ld	63	3	of	of	IN
cord-351517-npcuo1ld	63	4	the	the	DT
cord-351517-npcuo1ld	63	5	exhibit	exhibit	NN
cord-351517-npcuo1ld	63	6	areas	area	NNS
cord-351517-npcuo1ld	63	7	at	at	IN
cord-351517-npcuo1ld	63	8	the	the	DT
cord-351517-npcuo1ld	63	9	TCT	TCT	NNP
cord-351517-npcuo1ld	63	10	and	and	CC
cord-351517-npcuo1ld	63	11	EBMT	EBMT	NNP
cord-351517-npcuo1ld	63	12	meetings	meeting	NNS
cord-351517-npcuo1ld	63	13	.	.	.
cord-351517-npcuo1ld	64	1	Our	-PRON-	PRP$
cord-351517-npcuo1ld	64	2	point	point	NN
cord-351517-npcuo1ld	64	3	is	be	VBZ
cord-351517-npcuo1ld	64	4	that	that	IN
cord-351517-npcuo1ld	64	5	although	although	IN
cord-351517-npcuo1ld	64	6	its	-PRON-	PRP$
cord-351517-npcuo1ld	64	7	popular	popular	JJ
cord-351517-npcuo1ld	64	8	to	to	TO
cord-351517-npcuo1ld	64	9	disparage	disparage	VB
cord-351517-npcuo1ld	64	10	the	the	DT
cord-351517-npcuo1ld	64	11	drug	drug	NN
cord-351517-npcuo1ld	64	12	industry	industry	NN
cord-351517-npcuo1ld	64	13	for	for	IN
cord-351517-npcuo1ld	64	14	promoting	promote	VBG
cord-351517-npcuo1ld	64	15	new	new	JJ
cord-351517-npcuo1ld	64	16	drugs	drug	NNS
cord-351517-npcuo1ld	64	17	with	with	IN
cord-351517-npcuo1ld	64	18	sometimes	sometimes	RB
cord-351517-npcuo1ld	64	19	marginal	marginal	JJ
cord-351517-npcuo1ld	64	20	benefits	benefit	NNS
cord-351517-npcuo1ld	64	21	and	and	CC
cord-351517-npcuo1ld	64	22	high	high	JJ
cord-351517-npcuo1ld	64	23	costs	cost	NNS
cord-351517-npcuo1ld	64	24	,	,	,
cord-351517-npcuo1ld	64	25	the	the	DT
cord-351517-npcuo1ld	64	26	medical	medical	JJ
cord-351517-npcuo1ld	64	27	community	community	NN
cord-351517-npcuo1ld	64	28	benefits	benefit	NNS
cord-351517-npcuo1ld	64	29	greatly	greatly	RB
cord-351517-npcuo1ld	64	30	from	from	IN
cord-351517-npcuo1ld	64	31	the	the	DT
cord-351517-npcuo1ld	64	32	investment	investment	NN
cord-351517-npcuo1ld	64	33	of	of	IN
cord-351517-npcuo1ld	64	34	these	these	DT
cord-351517-npcuo1ld	64	35	drug	drug	NN
cord-351517-npcuo1ld	64	36	companies	company	NNS
cord-351517-npcuo1ld	64	37	.	.	.
cord-351517-npcuo1ld	65	1	Much	much	JJ
cord-351517-npcuo1ld	65	2	of	of	IN
cord-351517-npcuo1ld	65	3	our	-PRON-	PRP$
cord-351517-npcuo1ld	65	4	medical	medical	JJ
cord-351517-npcuo1ld	65	5	education	education	NN
cord-351517-npcuo1ld	65	6	in	in	IN
cord-351517-npcuo1ld	65	7	diverse	diverse	JJ
cord-351517-npcuo1ld	65	8	areas	area	NNS
cord-351517-npcuo1ld	65	9	is	be	VBZ
cord-351517-npcuo1ld	65	10	indirectly	indirectly	RB
cord-351517-npcuo1ld	65	11	supported	support	VBN
cord-351517-npcuo1ld	65	12	by	by	IN
cord-351517-npcuo1ld	65	13	the	the	DT
cord-351517-npcuo1ld	65	14	drug	drug	NN
cord-351517-npcuo1ld	65	15	industry	industry	NN
cord-351517-npcuo1ld	65	16	.	.	.
cord-351517-npcuo1ld	66	1	Our	-PRON-	PRP$
cord-351517-npcuo1ld	66	2	lives	life	NNS
cord-351517-npcuo1ld	66	3	would	would	MD
cord-351517-npcuo1ld	66	4	be	be	VB
cord-351517-npcuo1ld	66	5	entirely	entirely	RB
cord-351517-npcuo1ld	66	6	different	different	JJ
cord-351517-npcuo1ld	66	7	if	if	IN
cord-351517-npcuo1ld	66	8	drug	drug	NN
cord-351517-npcuo1ld	66	9	companies	company	NNS
cord-351517-npcuo1ld	66	10	developing	develop	VBG
cord-351517-npcuo1ld	66	11	and	and	CC
cord-351517-npcuo1ld	66	12	promoting	promote	VBG
cord-351517-npcuo1ld	66	13	new	new	JJ
cord-351517-npcuo1ld	66	14	drugs	drug	NNS
cord-351517-npcuo1ld	66	15	ceased	cease	VBD
cord-351517-npcuo1ld	66	16	to	to	TO
cord-351517-npcuo1ld	66	17	exist	exist	VB
cord-351517-npcuo1ld	66	18	.	.	.
cord-351517-npcuo1ld	67	1	And	and	CC
cord-351517-npcuo1ld	67	2	we	-PRON-	PRP
cord-351517-npcuo1ld	67	3	would	would	MD
cord-351517-npcuo1ld	67	4	be	be	VB
cord-351517-npcuo1ld	67	5	eating	eat	VBG
cord-351517-npcuo1ld	67	6	hot	hot	JJ
cord-351517-npcuo1ld	67	7	dogs	dog	NNS
cord-351517-npcuo1ld	67	8	at	at	IN
cord-351517-npcuo1ld	67	9	Nathan	Nathan	NNP
cord-351517-npcuo1ld	67	10	's	's	POS
cord-351517-npcuo1ld	67	11	rather	rather	RB
cord-351517-npcuo1ld	67	12	than	than	IN
cord-351517-npcuo1ld	67	13	black	black	JJ
cord-351517-npcuo1ld	67	14	cod	cod	NN
cord-351517-npcuo1ld	67	15	in	in	IN
cord-351517-npcuo1ld	67	16	miso	miso	NN
cord-351517-npcuo1ld	67	17	at	at	IN
cord-351517-npcuo1ld	67	18	Nobu	Nobu	NNP
cord-351517-npcuo1ld	67	19	.	.	.
cord-351517-npcuo1ld	68	1	Remember	remember	VB
cord-351517-npcuo1ld	68	2	,	,	,
cord-351517-npcuo1ld	68	3	the	the	DT
cord-351517-npcuo1ld	68	4	estimated	estimate	VBN
cord-351517-npcuo1ld	68	5	cost	cost	NN
cord-351517-npcuo1ld	68	6	of	of	IN
cord-351517-npcuo1ld	68	7	bringing	bring	VBG
cord-351517-npcuo1ld	68	8	a	a	DT
cord-351517-npcuo1ld	68	9	new	new	JJ
cord-351517-npcuo1ld	68	10	cancer	cancer	NN
cord-351517-npcuo1ld	68	11	drug	drug	NN
cord-351517-npcuo1ld	68	12	to	to	IN
cord-351517-npcuo1ld	68	13	approval	approval	NN
cord-351517-npcuo1ld	68	14	is	be	VBZ
cord-351517-npcuo1ld	68	15	about	about	RB
cord-351517-npcuo1ld	68	16	$	$	$
cord-351517-npcuo1ld	68	17	700	700	CD
cord-351517-npcuo1ld	68	18	million	million	CD
cord-351517-npcuo1ld	68	19	USD	usd	NN
cord-351517-npcuo1ld	68	20	[	[	-LRB-
cord-351517-npcuo1ld	68	21	9	9	CD
cord-351517-npcuo1ld	68	22	]	]	-RRB-
cord-351517-npcuo1ld	68	23	.	.	.
cord-351517-npcuo1ld	69	1	These	these	DT
cord-351517-npcuo1ld	69	2	monies	monie	NNS
cord-351517-npcuo1ld	69	3	come	come	VBP
cord-351517-npcuo1ld	69	4	from	from	IN
cord-351517-npcuo1ld	69	5	drug	drug	NN
cord-351517-npcuo1ld	69	6	company	company	NN
cord-351517-npcuo1ld	69	7	research	research	NN
cord-351517-npcuo1ld	69	8	and	and	CC
cord-351517-npcuo1ld	69	9	development	development	NN
cord-351517-npcuo1ld	69	10	and	and	CC
cord-351517-npcuo1ld	69	11	need	need	VBP
cord-351517-npcuo1ld	69	12	to	to	TO
cord-351517-npcuo1ld	69	13	be	be	VB
cord-351517-npcuo1ld	69	14	returned	return	VBN
cord-351517-npcuo1ld	69	15	to	to	IN
cord-351517-npcuo1ld	69	16	stockholders	stockholder	NNS
cord-351517-npcuo1ld	69	17	with	with	IN
cord-351517-npcuo1ld	69	18	a	a	DT
cord-351517-npcuo1ld	69	19	profit	profit	NN
cord-351517-npcuo1ld	69	20	.	.	.
cord-351517-npcuo1ld	70	1	Have	have	VBP
cord-351517-npcuo1ld	70	2	we	-PRON-	PRP
cord-351517-npcuo1ld	70	3	a	a	DT
cord-351517-npcuo1ld	70	4	solution	solution	NN
cord-351517-npcuo1ld	70	5	to	to	IN
cord-351517-npcuo1ld	70	6	these	these	DT
cord-351517-npcuo1ld	70	7	potential	potential	JJ
cord-351517-npcuo1ld	70	8	liaisons	liaison	NNS
cord-351517-npcuo1ld	70	9	dangereuses	dangereuse	NNS
cord-351517-npcuo1ld	70	10	likely	likely	JJ
cord-351517-npcuo1ld	70	11	to	to	TO
cord-351517-npcuo1ld	70	12	work	work	VB
cord-351517-npcuo1ld	70	13	?	?	.
cord-351517-npcuo1ld	71	1	No	no	UH
cord-351517-npcuo1ld	71	2	.	.	.
cord-351517-npcuo1ld	72	1	It	-PRON-	PRP
cord-351517-npcuo1ld	72	2	is	be	VBZ
cord-351517-npcuo1ld	72	3	unreasonable	unreasonable	JJ
cord-351517-npcuo1ld	72	4	to	to	TO
cord-351517-npcuo1ld	72	5	expect	expect	VB
cord-351517-npcuo1ld	72	6	drug	drug	NN
cord-351517-npcuo1ld	72	7	companies	company	NNS
cord-351517-npcuo1ld	72	8	not	not	RB
cord-351517-npcuo1ld	72	9	to	to	TO
cord-351517-npcuo1ld	72	10	promote	promote	VB
cord-351517-npcuo1ld	72	11	drugs	drug	NNS
cord-351517-npcuo1ld	72	12	they	-PRON-	PRP
cord-351517-npcuo1ld	72	13	have	have	VBP
cord-351517-npcuo1ld	72	14	developed	develop	VBN
cord-351517-npcuo1ld	72	15	at	at	IN
cord-351517-npcuo1ld	72	16	great	great	JJ
cord-351517-npcuo1ld	72	17	cost	cost	NN
cord-351517-npcuo1ld	72	18	.	.	.
cord-351517-npcuo1ld	73	1	Professional	professional	JJ
cord-351517-npcuo1ld	73	2	societies	society	NNS
cord-351517-npcuo1ld	73	3	and	and	CC
cord-351517-npcuo1ld	73	4	publishers	publisher	NNS
cord-351517-npcuo1ld	73	5	are	be	VBP
cord-351517-npcuo1ld	73	6	addicted	addicted	JJ
cord-351517-npcuo1ld	73	7	to	to	IN
cord-351517-npcuo1ld	73	8	drug	drug	NN
cord-351517-npcuo1ld	73	9	company	company	NN
cord-351517-npcuo1ld	73	10	support	support	NN
cord-351517-npcuo1ld	73	11	.	.	.
cord-351517-npcuo1ld	74	1	Individual	individual	JJ
cord-351517-npcuo1ld	74	2	investigators	investigator	NNS
cord-351517-npcuo1ld	74	3	fight	fight	VBP
cord-351517-npcuo1ld	74	4	to	to	TO
cord-351517-npcuo1ld	74	5	participate	participate	VB
cord-351517-npcuo1ld	74	6	in	in	IN
cord-351517-npcuo1ld	74	7	clinical	clinical	JJ
cord-351517-npcuo1ld	74	8	trials	trial	NNS
cord-351517-npcuo1ld	74	9	of	of	IN
cord-351517-npcuo1ld	74	10	interesting	interesting	JJ
cord-351517-npcuo1ld	74	11	drugs	drug	NNS
cord-351517-npcuo1ld	74	12	.	.	.
cord-351517-npcuo1ld	75	1	Coinvestigators	coinvestigator	NNS
cord-351517-npcuo1ld	75	2	fight	fight	VBP
cord-351517-npcuo1ld	75	3	for	for	IN
cord-351517-npcuo1ld	75	4	lead	lead	JJ
cord-351517-npcuo1ld	75	5	authourship	authourship	NN
cord-351517-npcuo1ld	75	6	on	on	IN
cord-351517-npcuo1ld	75	7	publications	publication	NNS
cord-351517-npcuo1ld	75	8	of	of	IN
cord-351517-npcuo1ld	75	9	successful	successful	JJ
cord-351517-npcuo1ld	75	10	drug	drug	NN
cord-351517-npcuo1ld	75	11	trials	trial	NNS
cord-351517-npcuo1ld	75	12	which	which	WDT
cord-351517-npcuo1ld	75	13	come	come	VBP
cord-351517-npcuo1ld	75	14	with	with	IN
cord-351517-npcuo1ld	75	15	designation	designation	NN
cord-351517-npcuo1ld	75	16	as	as	IN
cord-351517-npcuo1ld	75	17	a	a	DT
cord-351517-npcuo1ld	75	18	KOL	KOL	NNP
cord-351517-npcuo1ld	75	19	and	and	CC
cord-351517-npcuo1ld	75	20	extensive	extensive	JJ
cord-351517-npcuo1ld	75	21	travel	travel	NN
cord-351517-npcuo1ld	75	22	on	on	IN
cord-351517-npcuo1ld	75	23	what	what	WP
cord-351517-npcuo1ld	75	24	are	be	VBP
cord-351517-npcuo1ld	75	25	labeled	label	VBN
cord-351517-npcuo1ld	75	26	educational	educational	JJ
cord-351517-npcuo1ld	75	27	symposia	symposium	NNS
cord-351517-npcuo1ld	75	28	.	.	.
cord-351517-npcuo1ld	76	1	Regulatory	regulatory	JJ
cord-351517-npcuo1ld	76	2	agencies	agency	NNS
cord-351517-npcuo1ld	76	3	such	such	JJ
cord-351517-npcuo1ld	76	4	as	as	IN
cord-351517-npcuo1ld	76	5	US	US	NNP
cord-351517-npcuo1ld	76	6	FDA	FDA	NNP
cord-351517-npcuo1ld	76	7	and	and	CC
cord-351517-npcuo1ld	76	8	EMA	EMA	NNP
cord-351517-npcuo1ld	76	9	have	have	VBP
cord-351517-npcuo1ld	76	10	helped	help	VBN
cord-351517-npcuo1ld	76	11	curb	curb	VB
cord-351517-npcuo1ld	76	12	inappropriate	inappropriate	JJ
cord-351517-npcuo1ld	76	13	drug	drug	NN
cord-351517-npcuo1ld	76	14	labeling	labeling	NN
cord-351517-npcuo1ld	76	15	and	and	CC
cord-351517-npcuo1ld	76	16	promotional	promotional	JJ
cord-351517-npcuo1ld	76	17	activities	activity	NNS
cord-351517-npcuo1ld	76	18	but	but	CC
cord-351517-npcuo1ld	76	19	have	have	VBP
cord-351517-npcuo1ld	76	20	limited	limit	VBN
cord-351517-npcuo1ld	76	21	jurisdiction	jurisdiction	NN
cord-351517-npcuo1ld	76	22	and	and	CC
cord-351517-npcuo1ld	76	23	are	be	VBP
cord-351517-npcuo1ld	76	24	subject	subject	JJ
cord-351517-npcuo1ld	76	25	to	to	IN
cord-351517-npcuo1ld	76	26	political	political	JJ
cord-351517-npcuo1ld	76	27	influences	influence	NNS
cord-351517-npcuo1ld	76	28	.	.	.
cord-351517-npcuo1ld	77	1	In	in	IN
cord-351517-npcuo1ld	77	2	the	the	DT
cord-351517-npcuo1ld	77	3	US	US	NNP
cord-351517-npcuo1ld	77	4	,	,	,
cord-351517-npcuo1ld	77	5	FDA	FDA	NNP
cord-351517-npcuo1ld	77	6	is	be	VBZ
cord-351517-npcuo1ld	77	7	required	require	VBN
cord-351517-npcuo1ld	77	8	by	by	IN
cord-351517-npcuo1ld	77	9	law	law	NN
cord-351517-npcuo1ld	77	10	to	to	TO
cord-351517-npcuo1ld	77	11	approve	approve	VB
cord-351517-npcuo1ld	77	12	any	any	DT
cord-351517-npcuo1ld	77	13	drug	drug	NN
cord-351517-npcuo1ld	77	14	determined	determine	VBD
cord-351517-npcuo1ld	77	15	safe	safe	JJ
cord-351517-npcuo1ld	77	16	and	and	CC
cord-351517-npcuo1ld	77	17	effective	effective	JJ
cord-351517-npcuo1ld	77	18	whether	whether	IN
cord-351517-npcuo1ld	77	19	or	or	CC
cord-351517-npcuo1ld	77	20	not	not	RB
cord-351517-npcuo1ld	77	21	the	the	DT
cord-351517-npcuo1ld	77	22	new	new	JJ
cord-351517-npcuo1ld	77	23	drug	drug	NN
cord-351517-npcuo1ld	77	24	is	be	VBZ
cord-351517-npcuo1ld	77	25	safer	safe	JJR
cord-351517-npcuo1ld	77	26	or	or	CC
cord-351517-npcuo1ld	77	27	better	well	JJR
cord-351517-npcuo1ld	77	28	than	than	IN
cord-351517-npcuo1ld	77	29	a	a	DT
cord-351517-npcuo1ld	77	30	current	current	JJ
cord-351517-npcuo1ld	77	31	drug	drug	NN
cord-351517-npcuo1ld	77	32	.	.	.
cord-351517-npcuo1ld	78	1	Price	price	NN
cord-351517-npcuo1ld	78	2	is	be	VBZ
cord-351517-npcuo1ld	78	3	dictated	dictate	VBN
cord-351517-npcuo1ld	78	4	by	by	IN
cord-351517-npcuo1ld	78	5	the	the	DT
cord-351517-npcuo1ld	78	6	drug	drug	NN
cord-351517-npcuo1ld	78	7	company	company	NN
cord-351517-npcuo1ld	78	8	,	,	,
cord-351517-npcuo1ld	78	9	not	not	RB
cord-351517-npcuo1ld	78	10	the	the	DT
cord-351517-npcuo1ld	78	11	FDA	FDA	NNP
cord-351517-npcuo1ld	78	12	.	.	.
cord-351517-npcuo1ld	79	1	Cost	cost	NN
cord-351517-npcuo1ld	79	2	control	control	NN
cord-351517-npcuo1ld	79	3	(	(	-LRB-
cord-351517-npcuo1ld	79	4	if	if	IN
cord-351517-npcuo1ld	79	5	any	any	DT
cord-351517-npcuo1ld	79	6	)	)	-RRB-
cord-351517-npcuo1ld	79	7	lies	lie	VBZ
cord-351517-npcuo1ld	79	8	with	with	IN
cord-351517-npcuo1ld	79	9	the	the	DT
cord-351517-npcuo1ld	79	10	Centers	Centers	NNPS
cord-351517-npcuo1ld	79	11	for	for	IN
cord-351517-npcuo1ld	79	12	Medicare	Medicare	NNP
cord-351517-npcuo1ld	79	13	and	and	CC
cord-351517-npcuo1ld	79	14	Medicaid	Medicaid	NNP
cord-351517-npcuo1ld	79	15	Services	Services	NNP
cord-351517-npcuo1ld	79	16	(	(	-LRB-
cord-351517-npcuo1ld	79	17	CMS	CMS	NNP
cord-351517-npcuo1ld	79	18	)	)	-RRB-
cord-351517-npcuo1ld	79	19	,	,	,
cord-351517-npcuo1ld	79	20	payor	payor	NN
cord-351517-npcuo1ld	79	21	for	for	IN
cord-351517-npcuo1ld	79	22	Americans	Americans	NNPS
cord-351517-npcuo1ld	79	23	without	without	IN
cord-351517-npcuo1ld	79	24	medical	medical	JJ
cord-351517-npcuo1ld	79	25	insurance	insurance	NN
cord-351517-npcuo1ld	79	26	and	and	CC
cord-351517-npcuo1ld	79	27	for	for	IN
cord-351517-npcuo1ld	79	28	persons	person	NNS
cord-351517-npcuo1ld	79	29	>	>	NFP
cord-351517-npcuo1ld	79	30	65	65	CD
cord-351517-npcuo1ld	79	31	years	year	NNS
cord-351517-npcuo1ld	79	32	and	and	CC
cord-351517-npcuo1ld	79	33	with	with	IN
cord-351517-npcuo1ld	79	34	pharmacy	pharmacy	NN
cord-351517-npcuo1ld	79	35	benefit	benefit	NN
cord-351517-npcuo1ld	79	36	managers	manager	NNS
cord-351517-npcuo1ld	79	37	who	who	WP
cord-351517-npcuo1ld	79	38	affect	affect	VBP
cord-351517-npcuo1ld	79	39	discounts	discount	NNS
cord-351517-npcuo1ld	79	40	,	,	,
cord-351517-npcuo1ld	79	41	not	not	RB
cord-351517-npcuo1ld	79	42	price	price	NN
cord-351517-npcuo1ld	79	43	.	.	.
cord-351517-npcuo1ld	80	1	Moreover	moreover	RB
cord-351517-npcuo1ld	80	2	,	,	,
cord-351517-npcuo1ld	80	3	US	US	NNP
cord-351517-npcuo1ld	80	4	physicians	physician	NNS
cord-351517-npcuo1ld	80	5	can	can	MD
cord-351517-npcuo1ld	80	6	prescribe	prescribe	VB
cord-351517-npcuo1ld	80	7	any	any	DT
cord-351517-npcuo1ld	80	8	FDA	FDA	NNP
cord-351517-npcuo1ld	80	9	-	-	HYPH
cord-351517-npcuo1ld	80	10	approved	approve	VBN
cord-351517-npcuo1ld	80	11	drug	drug	NN
cord-351517-npcuo1ld	80	12	in	in	IN
cord-351517-npcuo1ld	80	13	settings	setting	NNS
cord-351517-npcuo1ld	80	14	different	different	JJ
cord-351517-npcuo1ld	80	15	from	from	IN
cord-351517-npcuo1ld	80	16	those	those	DT
cord-351517-npcuo1ld	80	17	for	for	IN
cord-351517-npcuo1ld	80	18	which	which	WDT
cord-351517-npcuo1ld	80	19	the	the	DT
cord-351517-npcuo1ld	80	20	drug	drug	NN
cord-351517-npcuo1ld	80	21	was	be	VBD
cord-351517-npcuo1ld	80	22	approved	approve	VBN
cord-351517-npcuo1ld	80	23	,	,	,
cord-351517-npcuo1ld	80	24	a	a	DT
cord-351517-npcuo1ld	80	25	practice	practice	NN
cord-351517-npcuo1ld	80	26	termed	term	VBN
cord-351517-npcuo1ld	80	27	off	off	IN
cord-351517-npcuo1ld	80	28	-	-	HYPH
cord-351517-npcuo1ld	80	29	label	label	NN
cord-351517-npcuo1ld	80	30	use	use	NN
cord-351517-npcuo1ld	80	31	.	.	.
cord-351517-npcuo1ld	81	1	Again	again	RB
cord-351517-npcuo1ld	81	2	,	,	,
cord-351517-npcuo1ld	81	3	the	the	DT
cord-351517-npcuo1ld	81	4	only	only	JJ
cord-351517-npcuo1ld	81	5	control	control	NN
cord-351517-npcuo1ld	81	6	of	of	IN
cord-351517-npcuo1ld	81	7	off	off	IN
cord-351517-npcuo1ld	81	8	-	-	HYPH
cord-351517-npcuo1ld	81	9	label	label	NN
cord-351517-npcuo1ld	81	10	use	use	NN
cord-351517-npcuo1ld	81	11	are	be	VBP
cord-351517-npcuo1ld	81	12	payors	payor	NNS
cord-351517-npcuo1ld	81	13	.	.	.
cord-351517-npcuo1ld	82	1	Controls	control	NNS
cord-351517-npcuo1ld	82	2	of	of	IN
cord-351517-npcuo1ld	82	3	drug	drug	NN
cord-351517-npcuo1ld	82	4	use	use	NN
cord-351517-npcuo1ld	82	5	and	and	CC
cord-351517-npcuo1ld	82	6	pricing	pricing	NN
cord-351517-npcuo1ld	82	7	are	be	VBP
cord-351517-npcuo1ld	82	8	different	different	JJ
cord-351517-npcuo1ld	82	9	in	in	IN
cord-351517-npcuo1ld	82	10	some	some	DT
cord-351517-npcuo1ld	82	11	other	other	JJ
cord-351517-npcuo1ld	82	12	countries	country	NNS
cord-351517-npcuo1ld	82	13	such	such	JJ
cord-351517-npcuo1ld	82	14	as	as	IN
cord-351517-npcuo1ld	82	15	the	the	DT
cord-351517-npcuo1ld	82	16	UK	UK	NNP
cord-351517-npcuo1ld	82	17	where	where	WRB
cord-351517-npcuo1ld	82	18	approval	approval	NN
cord-351517-npcuo1ld	82	19	based	base	VBN
cord-351517-npcuo1ld	82	20	on	on	IN
cord-351517-npcuo1ld	82	21	a	a	DT
cord-351517-npcuo1ld	82	22	determination	determination	NN
cord-351517-npcuo1ld	82	23	of	of	IN
cord-351517-npcuo1ld	82	24	safety	safety	NN
cord-351517-npcuo1ld	82	25	and	and	CC
cord-351517-npcuo1ld	82	26	efficacy	efficacy	NN
cord-351517-npcuo1ld	82	27	is	be	VBZ
cord-351517-npcuo1ld	82	28	done	do	VBN
cord-351517-npcuo1ld	82	29	by	by	IN
cord-351517-npcuo1ld	82	30	one	one	CD
cord-351517-npcuo1ld	82	31	Health	Health	NNP
cord-351517-npcuo1ld	82	32	Authority	Authority	NNP
cord-351517-npcuo1ld	82	33	(	(	-LRB-
cord-351517-npcuo1ld	82	34	Medicines	Medicines	NNP
cord-351517-npcuo1ld	82	35	and	and	CC
cord-351517-npcuo1ld	82	36	Health	Health	NNP
cord-351517-npcuo1ld	82	37	care	care	NN
cord-351517-npcuo1ld	82	38	Products	Products	NNP
cord-351517-npcuo1ld	82	39	Regulatory	Regulatory	NNP
cord-351517-npcuo1ld	82	40	Agency	Agency	NNP
cord-351517-npcuo1ld	82	41	)	)	-RRB-
cord-351517-npcuo1ld	83	1	and	and	CC
cord-351517-npcuo1ld	83	2	appropriateness	appropriateness	NN
cord-351517-npcuo1ld	83	3	of	of	IN
cord-351517-npcuo1ld	83	4	use	use	NN
cord-351517-npcuo1ld	83	5	and	and	CC
cord-351517-npcuo1ld	83	6	price	price	NN
cord-351517-npcuo1ld	83	7	are	be	VBP
cord-351517-npcuo1ld	83	8	determined	determine	VBN
cord-351517-npcuo1ld	83	9	by	by	IN
cord-351517-npcuo1ld	83	10	another	another	DT
cord-351517-npcuo1ld	83	11	agency	agency	NN
cord-351517-npcuo1ld	83	12	(	(	-LRB-
cord-351517-npcuo1ld	83	13	National	National	NNP
cord-351517-npcuo1ld	83	14	Institute	Institute	NNP
cord-351517-npcuo1ld	83	15	for	for	IN
cord-351517-npcuo1ld	83	16	Health	Health	NNP
cord-351517-npcuo1ld	83	17	and	and	CC
cord-351517-npcuo1ld	83	18	Care	Care	NNP
cord-351517-npcuo1ld	83	19	Excellence	Excellence	NNP
cord-351517-npcuo1ld	83	20	(	(	-LRB-
cord-351517-npcuo1ld	83	21	NICE	NICE	NNP
cord-351517-npcuo1ld	83	22	)	)	-RRB-
cord-351517-npcuo1ld	83	23	.	.	.
cord-351517-npcuo1ld	84	1	Can	Can	MD
cord-351517-npcuo1ld	84	2	we	-PRON-	PRP
cord-351517-npcuo1ld	84	3	correct	correct	VB
cord-351517-npcuo1ld	84	4	the	the	DT
cord-351517-npcuo1ld	84	5	threat	threat	NN
cord-351517-npcuo1ld	84	6	of	of	IN
cord-351517-npcuo1ld	84	7	liaisons	liaison	NNS
cord-351517-npcuo1ld	84	8	dangereuses	dangereuse	NNS
cord-351517-npcuo1ld	84	9	?	?	.
cord-351517-npcuo1ld	85	1	There	there	EX
cord-351517-npcuo1ld	85	2	are	be	VBP
cord-351517-npcuo1ld	85	3	some	some	DT
cord-351517-npcuo1ld	85	4	rays	ray	NNS
cord-351517-npcuo1ld	85	5	of	of	IN
cord-351517-npcuo1ld	85	6	hope	hope	NN
cord-351517-npcuo1ld	85	7	.	.	.
cord-351517-npcuo1ld	86	1	In	in	IN
cord-351517-npcuo1ld	86	2	the	the	DT
cord-351517-npcuo1ld	86	3	US	US	NNP
cord-351517-npcuo1ld	86	4	CMS	CMS	NNP
cord-351517-npcuo1ld	86	5	and	and	CC
cord-351517-npcuo1ld	86	6	the	the	DT
cord-351517-npcuo1ld	86	7	State	State	NNP
cord-351517-npcuo1ld	86	8	Children	Children	NNPS
cord-351517-npcuo1ld	86	9	's	's	POS
cord-351517-npcuo1ld	86	10	Insurance	Insurance	NNP
cord-351517-npcuo1ld	86	11	Program	Program	NNP
cord-351517-npcuo1ld	86	12	are	be	VBP
cord-351517-npcuo1ld	86	13	required	require	VBN
cord-351517-npcuo1ld	86	14	to	to	TO
cord-351517-npcuo1ld	86	15	enforce	enforce	VB
cord-351517-npcuo1ld	86	16	the	the	DT
cord-351517-npcuo1ld	86	17	Physicians	Physicians	NNP
cord-351517-npcuo1ld	86	18	Payments	Payments	NNP
cord-351517-npcuo1ld	86	19	Sunshine	Sunshine	NNP
cord-351517-npcuo1ld	86	20	Act	Act	NNP
cord-351517-npcuo1ld	86	21	which	which	WDT
cord-351517-npcuo1ld	86	22	requires	require	VBZ
cord-351517-npcuo1ld	86	23	drug	drug	NN
cord-351517-npcuo1ld	86	24	companies	company	NNS
cord-351517-npcuo1ld	86	25	to	to	TO
cord-351517-npcuo1ld	86	26	collect	collect	VB
cord-351517-npcuo1ld	86	27	and	and	CC
cord-351517-npcuo1ld	86	28	track	track	VB
cord-351517-npcuo1ld	86	29	all	all	DT
cord-351517-npcuo1ld	86	30	financial	financial	JJ
cord-351517-npcuo1ld	86	31	relationships	relationship	NNS
cord-351517-npcuo1ld	86	32	with	with	IN
cord-351517-npcuo1ld	86	33	physicians	physician	NNS
cord-351517-npcuo1ld	86	34	and	and	CC
cord-351517-npcuo1ld	86	35	teaching	teach	VBG
cord-351517-npcuo1ld	86	36	hospitals	hospital	NNS
cord-351517-npcuo1ld	86	37	.	.	.
cord-351517-npcuo1ld	87	1	The	the	DT
cord-351517-npcuo1ld	87	2	goal	goal	NN
cord-351517-npcuo1ld	87	3	is	be	VBZ
cord-351517-npcuo1ld	87	4	to	to	TO
cord-351517-npcuo1ld	87	5	increase	increase	VB
cord-351517-npcuo1ld	87	6	transparency	transparency	NN
cord-351517-npcuo1ld	87	7	of	of	IN
cord-351517-npcuo1ld	87	8	financial	financial	JJ
cord-351517-npcuo1ld	87	9	relationships	relationship	NNS
cord-351517-npcuo1ld	87	10	between	between	IN
cord-351517-npcuo1ld	87	11	health	health	NN
cord-351517-npcuo1ld	87	12	care	care	NN
cord-351517-npcuo1ld	87	13	providers	provider	NNS
cord-351517-npcuo1ld	87	14	and	and	CC
cord-351517-npcuo1ld	87	15	drug	drug	NN
cord-351517-npcuo1ld	87	16	companies	company	NNS
cord-351517-npcuo1ld	87	17	and	and	CC
cord-351517-npcuo1ld	87	18	uncover	uncover	VB
cord-351517-npcuo1ld	87	19	potential	potential	JJ
cord-351517-npcuo1ld	87	20	conflicts	conflict	NNS
cord-351517-npcuo1ld	87	21	of	of	IN
cord-351517-npcuo1ld	87	22	interest	interest	NN
cord-351517-npcuo1ld	87	23	.	.	.
cord-351517-npcuo1ld	88	1	The	the	DT
cord-351517-npcuo1ld	88	2	bill	bill	NN
cord-351517-npcuo1ld	88	3	also	also	RB
cord-351517-npcuo1ld	88	4	allows	allow	VBZ
cord-351517-npcuo1ld	88	5	states	state	NNS
cord-351517-npcuo1ld	88	6	to	to	TO
cord-351517-npcuo1ld	88	7	enact	enact	VB
cord-351517-npcuo1ld	88	8	additional	additional	JJ
cord-351517-npcuo1ld	88	9	requirements	requirement	NNS
cord-351517-npcuo1ld	88	10	which	which	WDT
cord-351517-npcuo1ld	88	11	several	several	JJ
cord-351517-npcuo1ld	88	12	states	state	NNS
cord-351517-npcuo1ld	88	13	have	have	VBP
cord-351517-npcuo1ld	88	14	done	do	VBN
cord-351517-npcuo1ld	88	15	.	.	.
cord-351517-npcuo1ld	89	1	Another	another	DT
cord-351517-npcuo1ld	89	2	step	step	NN
cord-351517-npcuo1ld	89	3	is	be	VBZ
cord-351517-npcuo1ld	89	4	that	that	IN
cord-351517-npcuo1ld	89	5	some	some	DT
cord-351517-npcuo1ld	89	6	universities	university	NNS
cord-351517-npcuo1ld	89	7	have	have	VBP
cord-351517-npcuo1ld	89	8	limited	limit	VBN
cord-351517-npcuo1ld	89	9	or	or	CC
cord-351517-npcuo1ld	89	10	completely	completely	RB
cord-351517-npcuo1ld	89	11	restricted	restricted	JJ
cord-351517-npcuo1ld	89	12	participation	participation	NN
cord-351517-npcuo1ld	89	13	of	of	IN
cord-351517-npcuo1ld	89	14	their	-PRON-	PRP$
cord-351517-npcuo1ld	89	15	faculty	faculty	NN
cord-351517-npcuo1ld	89	16	in	in	IN
cord-351517-npcuo1ld	89	17	promotional	promotional	JJ
cord-351517-npcuo1ld	89	18	activities	activity	NNS
cord-351517-npcuo1ld	89	19	.	.	.
cord-351517-npcuo1ld	90	1	However	however	RB
cord-351517-npcuo1ld	90	2	,	,	,
cord-351517-npcuo1ld	90	3	data	datum	NNS
cord-351517-npcuo1ld	90	4	on	on	IN
cord-351517-npcuo1ld	90	5	effectiveness	effectiveness	NN
cord-351517-npcuo1ld	90	6	of	of	IN
cord-351517-npcuo1ld	90	7	this	this	DT
cord-351517-npcuo1ld	90	8	ban	ban	NN
cord-351517-npcuo1ld	90	9	is	be	VBZ
cord-351517-npcuo1ld	90	10	far	far	RB
cord-351517-npcuo1ld	90	11	from	from	IN
cord-351517-npcuo1ld	90	12	promising	promise	VBG
cord-351517-npcuo1ld	90	13	[	[	-LRB-
cord-351517-npcuo1ld	90	14	10	10	CD
cord-351517-npcuo1ld	90	15	]	]	-RRB-
cord-351517-npcuo1ld	90	16	.	.	.
cord-351517-npcuo1ld	91	1	For	for	IN
cord-351517-npcuo1ld	91	2	example	example	NN
cord-351517-npcuo1ld	91	3	,	,	,
cord-351517-npcuo1ld	91	4	in	in	IN
cord-351517-npcuo1ld	91	5	a	a	DT
cord-351517-npcuo1ld	91	6	cohort	cohort	NN
cord-351517-npcuo1ld	91	7	of	of	IN
cord-351517-npcuo1ld	91	8	academic	academic	JJ
cord-351517-npcuo1ld	91	9	oncologists	oncologist	NNS
cord-351517-npcuo1ld	91	10	at	at	IN
cord-351517-npcuo1ld	91	11	US	US	NNP
cord-351517-npcuo1ld	91	12	public	public	JJ
cord-351517-npcuo1ld	91	13	medical	medical	JJ
cord-351517-npcuo1ld	91	14	schools	school	NNS
cord-351517-npcuo1ld	91	15	two	two	CD
cord-351517-npcuo1ld	91	16	-	-	HYPH
cord-351517-npcuo1ld	91	17	thirds	third	NNS
cord-351517-npcuo1ld	91	18	received	receive	VBD
cord-351517-npcuo1ld	91	19	payments	payment	NNS
cord-351517-npcuo1ld	91	20	from	from	IN
cord-351517-npcuo1ld	91	21	the	the	DT
cord-351517-npcuo1ld	91	22	drug	drug	NN
cord-351517-npcuo1ld	91	23	industry	industry	NN
cord-351517-npcuo1ld	91	24	in	in	IN
cord-351517-npcuo1ld	91	25	2017	2017	CD
cord-351517-npcuo1ld	91	26	accounting	account	VBG
cord-351517-npcuo1ld	91	27	for	for	IN
cord-351517-npcuo1ld	91	28	>	>	XX
cord-351517-npcuo1ld	91	29	20	20	CD
cord-351517-npcuo1ld	91	30	%	%	NN
cord-351517-npcuo1ld	91	31	of	of	IN
cord-351517-npcuo1ld	91	32	their	-PRON-	PRP$
cord-351517-npcuo1ld	91	33	annual	annual	JJ
cord-351517-npcuo1ld	91	34	salary	salary	NN
cord-351517-npcuo1ld	91	35	.	.	.
cord-351517-npcuo1ld	92	1	Recently	recently	RB
cord-351517-npcuo1ld	92	2	,	,	,
cord-351517-npcuo1ld	92	3	there	there	EX
cord-351517-npcuo1ld	92	4	has	have	VBZ
cord-351517-npcuo1ld	92	5	been	be	VBN
cord-351517-npcuo1ld	92	6	considerable	considerable	JJ
cord-351517-npcuo1ld	92	7	controversy	controversy	NN
cord-351517-npcuo1ld	92	8	over	over	IN
cord-351517-npcuo1ld	92	9	participation	participation	NN
cord-351517-npcuo1ld	92	10	in	in	IN
cord-351517-npcuo1ld	92	11	China	China	NNP
cord-351517-npcuo1ld	92	12	's	's	POS
cord-351517-npcuo1ld	92	13	Thousand	Thousand	NNP
cord-351517-npcuo1ld	92	14	Talents	Talents	NNPS
cord-351517-npcuo1ld	92	15	Plan	Plan	NNP
cord-351517-npcuo1ld	92	16	under	under	IN
cord-351517-npcuo1ld	92	17	which	which	WDT
cord-351517-npcuo1ld	92	18	US	US	NNP
cord-351517-npcuo1ld	92	19	academic	academic	JJ
cord-351517-npcuo1ld	92	20	physicians	physician	NNS
cord-351517-npcuo1ld	92	21	have	have	VBP
cord-351517-npcuo1ld	92	22	established	establish	VBN
cord-351517-npcuo1ld	92	23	relationships	relationship	NNS
cord-351517-npcuo1ld	92	24	with	with	IN
cord-351517-npcuo1ld	92	25	Chinese	chinese	JJ
cord-351517-npcuo1ld	92	26	universities	university	NNS
cord-351517-npcuo1ld	92	27	and	and	CC
cord-351517-npcuo1ld	92	28	,	,	,
cord-351517-npcuo1ld	92	29	in	in	IN
cord-351517-npcuo1ld	92	30	some	some	DT
cord-351517-npcuo1ld	92	31	instances	instance	NNS
cord-351517-npcuo1ld	92	32	,	,	,
cord-351517-npcuo1ld	92	33	drug	drug	NN
cord-351517-npcuo1ld	92	34	companies	company	NNS
cord-351517-npcuo1ld	92	35	receiving	receive	VBG
cord-351517-npcuo1ld	92	36	received	receive	VBD
cord-351517-npcuo1ld	92	37	substantial	substantial	JJ
cord-351517-npcuo1ld	92	38	research	research	NN
cord-351517-npcuo1ld	92	39	and	and	CC
cord-351517-npcuo1ld	92	40	personal	personal	JJ
cord-351517-npcuo1ld	92	41	monies	monie	NNS
cord-351517-npcuo1ld	92	42	.	.	.
cord-351517-npcuo1ld	93	1	The	the	DT
cord-351517-npcuo1ld	93	2	FBI	FBI	NNP
cord-351517-npcuo1ld	93	3	is	be	VBZ
cord-351517-npcuo1ld	93	4	currently	currently	RB
cord-351517-npcuo1ld	93	5	investigating	investigate	VBG
cord-351517-npcuo1ld	93	6	these	these	DT
cord-351517-npcuo1ld	93	7	relationships	relationship	NNS
cord-351517-npcuo1ld	93	8	which	which	WDT
cord-351517-npcuo1ld	93	9	have	have	VBP
cord-351517-npcuo1ld	93	10	led	lead	VBN
cord-351517-npcuo1ld	93	11	to	to	IN
cord-351517-npcuo1ld	93	12	the	the	DT
cord-351517-npcuo1ld	93	13	firing	firing	NN
cord-351517-npcuo1ld	93	14	of	of	IN
cord-351517-npcuo1ld	93	15	several	several	JJ
cord-351517-npcuo1ld	93	16	prominent	prominent	JJ
cord-351517-npcuo1ld	93	17	physician	physician	NN
cord-351517-npcuo1ld	93	18	scientists	scientist	NNS
cord-351517-npcuo1ld	93	19	.	.	.
cord-351517-npcuo1ld	94	1	None	none	NN
cord-351517-npcuo1ld	94	2	of	of	IN
cord-351517-npcuo1ld	94	3	these	these	DT
cord-351517-npcuo1ld	94	4	developments	development	NNS
cord-351517-npcuo1ld	94	5	is	be	VBZ
cord-351517-npcuo1ld	94	6	surprising	surprising	JJ
cord-351517-npcuo1ld	94	7	.	.	.
cord-351517-npcuo1ld	95	1	For	for	IN
cord-351517-npcuo1ld	95	2	example	example	NN
cord-351517-npcuo1ld	95	3	,	,	,
cord-351517-npcuo1ld	95	4	US	US	NNP
cord-351517-npcuo1ld	95	5	medical	medical	JJ
cord-351517-npcuo1ld	95	6	schools	school	NNS
cord-351517-npcuo1ld	95	7	have	have	VBP
cord-351517-npcuo1ld	95	8	been	be	VBN
cord-351517-npcuo1ld	95	9	selling	sell	VBG
cord-351517-npcuo1ld	95	10	themselves	-PRON-	PRP
cord-351517-npcuo1ld	95	11	for	for	IN
cord-351517-npcuo1ld	95	12	a	a	DT
cord-351517-npcuo1ld	95	13	price	price	NN
cord-351517-npcuo1ld	95	14	.	.	.
cord-351517-npcuo1ld	96	1	For	for	IN
cord-351517-npcuo1ld	96	2	a	a	DT
cord-351517-npcuo1ld	96	3	mere	mere	JJ
cord-351517-npcuo1ld	96	4	$	$	$
cord-351517-npcuo1ld	96	5	200	200	CD
cord-351517-npcuo1ld	96	6	million	million	CD
cord-351517-npcuo1ld	96	7	David	David	NNP
cord-351517-npcuo1ld	96	8	Geffin	Geffin	NNP
cord-351517-npcuo1ld	96	9	was	be	VBD
cord-351517-npcuo1ld	96	10	able	able	JJ
cord-351517-npcuo1ld	96	11	to	to	TO
cord-351517-npcuo1ld	96	12	have	have	VB
cord-351517-npcuo1ld	96	13	the	the	DT
cord-351517-npcuo1ld	96	14	UCLA	UCLA	NNP
cord-351517-npcuo1ld	96	15	School	School	NNP
cord-351517-npcuo1ld	96	16	of	of	IN
cord-351517-npcuo1ld	96	17	Medicine	Medicine	NNP
cord-351517-npcuo1ld	96	18	,	,	,
cord-351517-npcuo1ld	96	19	a	a	DT
cord-351517-npcuo1ld	96	20	state	state	NN
cord-351517-npcuo1ld	96	21	institution	institution	NN
cord-351517-npcuo1ld	96	22	,	,	,
cord-351517-npcuo1ld	96	23	named	name	VBN
cord-351517-npcuo1ld	96	24	for	for	IN
cord-351517-npcuo1ld	96	25	him	-PRON-	PRP
cord-351517-npcuo1ld	96	26	.	.	.
cord-351517-npcuo1ld	97	1	And	and	CC
cord-351517-npcuo1ld	97	2	UCLA	UCLA	NNP
cord-351517-npcuo1ld	97	3	Medical	Medical	NNP
cord-351517-npcuo1ld	97	4	Center	Center	NNP
cord-351517-npcuo1ld	97	5	is	be	VBZ
cord-351517-npcuo1ld	97	6	named	name	VBN
cord-351517-npcuo1ld	97	7	for	for	IN
cord-351517-npcuo1ld	97	8	ex	ex	NNP
cord-351517-npcuo1ld	97	9	-	-	JJ
cord-351517-npcuo1ld	97	10	President	President	NNP
cord-351517-npcuo1ld	97	11	Ronald	Ronald	NNP
cord-351517-npcuo1ld	97	12	Reagan	Reagan	NNP
cord-351517-npcuo1ld	97	13	after	after	IN
cord-351517-npcuo1ld	97	14	his	-PRON-	PRP$
cord-351517-npcuo1ld	97	15	friends	friend	NNS
cord-351517-npcuo1ld	97	16	donated	donate	VBD
cord-351517-npcuo1ld	97	17	$	$	$
cord-351517-npcuo1ld	97	18	150	150	CD
cord-351517-npcuo1ld	97	19	million	million	CD
cord-351517-npcuo1ld	97	20	.	.	.
cord-351517-npcuo1ld	98	1	(	(	-LRB-
cord-351517-npcuo1ld	98	2	Full	full	JJ
cord-351517-npcuo1ld	98	3	disclosure	disclosure	NN
cord-351517-npcuo1ld	98	4	:	:	:
cord-351517-npcuo1ld	98	5	RPGs	rpg	NNS
cord-351517-npcuo1ld	98	6	wife	wife	NN
cord-351517-npcuo1ld	98	7	is	be	VBZ
cord-351517-npcuo1ld	98	8	in	in	IN
cord-351517-npcuo1ld	98	9	the	the	DT
cord-351517-npcuo1ld	98	10	Case	Case	NNP
cord-351517-npcuo1ld	98	11	family	family	NN
cord-351517-npcuo1ld	98	12	of	of	IN
cord-351517-npcuo1ld	98	13	Case	Case	NNP
cord-351517-npcuo1ld	98	14	Western	Western	NNP
cord-351517-npcuo1ld	98	15	Reserve	Reserve	NNP
cord-351517-npcuo1ld	98	16	University	University	NNP
cord-351517-npcuo1ld	98	17	.	.	.
cord-351517-npcuo1ld	98	18	)	)	-RRB-
cord-351517-npcuo1ld	99	1	It	-PRON-	PRP
cord-351517-npcuo1ld	99	2	would	would	MD
cord-351517-npcuo1ld	99	3	seem	seem	VB
cord-351517-npcuo1ld	99	4	the	the	DT
cord-351517-npcuo1ld	99	5	California	California	NNP
cord-351517-npcuo1ld	99	6	Board	Board	NNP
cord-351517-npcuo1ld	99	7	of	of	IN
cord-351517-npcuo1ld	99	8	Regents	Regents	NNPS
cord-351517-npcuo1ld	99	9	would	would	MD
cord-351517-npcuo1ld	99	10	be	be	VB
cord-351517-npcuo1ld	99	11	on	on	IN
cord-351517-npcuo1ld	99	12	shaky	shaky	JJ
cord-351517-npcuo1ld	99	13	moral	moral	JJ
cord-351517-npcuo1ld	99	14	ground	ground	NN
cord-351517-npcuo1ld	99	15	trying	try	VBG
cord-351517-npcuo1ld	99	16	to	to	TO
cord-351517-npcuo1ld	99	17	control	control	VB
cord-351517-npcuo1ld	99	18	physicians	physician	NNS
cord-351517-npcuo1ld	99	19	'	'	POS
cord-351517-npcuo1ld	99	20	drug	drug	NN
cord-351517-npcuo1ld	99	21	prescribing	prescribing	NN
cord-351517-npcuo1ld	99	22	activities	activity	NNS
cord-351517-npcuo1ld	99	23	.	.	.
cord-351517-npcuo1ld	100	1	The	the	DT
cord-351517-npcuo1ld	100	2	truth	truth	NN
cord-351517-npcuo1ld	100	3	is	be	VBZ
cord-351517-npcuo1ld	100	4	physicians	physician	NNS
cord-351517-npcuo1ld	100	5	and	and	CC
cord-351517-npcuo1ld	100	6	the	the	DT
cord-351517-npcuo1ld	100	7	drug	drug	NN
cord-351517-npcuo1ld	100	8	industry	industry	NN
cord-351517-npcuo1ld	100	9	have	have	VBP
cord-351517-npcuo1ld	100	10	a	a	DT
cord-351517-npcuo1ld	100	11	symbiotic	symbiotic	JJ
cord-351517-npcuo1ld	100	12	relationship	relationship	NN
cord-351517-npcuo1ld	100	13	.	.	.
cord-351517-npcuo1ld	101	1	Physicians	physician	NNS
cord-351517-npcuo1ld	101	2	like	like	VBP
cord-351517-npcuo1ld	101	3	to	to	TO
cord-351517-npcuo1ld	101	4	complain	complain	VB
cord-351517-npcuo1ld	102	1	but	but	CC
cord-351517-npcuo1ld	102	2	nobody	nobody	NN
cord-351517-npcuo1ld	102	3	really	really	RB
cord-351517-npcuo1ld	102	4	wants	want	VBZ
cord-351517-npcuo1ld	102	5	change	change	NN
cord-351517-npcuo1ld	102	6	.	.	.
cord-351517-npcuo1ld	103	1	But	but	CC
cord-351517-npcuo1ld	103	2	there	there	EX
cord-351517-npcuo1ld	103	3	is	be	VBZ
cord-351517-npcuo1ld	103	4	hope	hope	NN
cord-351517-npcuo1ld	103	5	because	because	IN
cord-351517-npcuo1ld	103	6	what	what	WP
cord-351517-npcuo1ld	103	7	ultimately	ultimately	RB
cord-351517-npcuo1ld	103	8	saves	save	VBZ
cord-351517-npcuo1ld	103	9	us	-PRON-	PRP
cord-351517-npcuo1ld	103	10	from	from	IN
cord-351517-npcuo1ld	103	11	these	these	DT
cord-351517-npcuo1ld	103	12	liaisons	liaison	NNS
cord-351517-npcuo1ld	103	13	dangereuses	dangereuse	NNS
cord-351517-npcuo1ld	103	14	is	be	VBZ
cord-351517-npcuo1ld	103	15	the	the	DT
cord-351517-npcuo1ld	103	16	moral	moral	JJ
cord-351517-npcuo1ld	103	17	compass	compass	NN
cord-351517-npcuo1ld	103	18	of	of	IN
cord-351517-npcuo1ld	103	19	most	most	JJS
cord-351517-npcuo1ld	103	20	physicians	physician	NNS
cord-351517-npcuo1ld	103	21	who	who	WP
cord-351517-npcuo1ld	103	22	want	want	VBP
cord-351517-npcuo1ld	103	23	to	to	TO
cord-351517-npcuo1ld	103	24	do	do	VB
cord-351517-npcuo1ld	103	25	what	what	WP
cord-351517-npcuo1ld	103	26	's	be	VBZ
cord-351517-npcuo1ld	103	27	best	good	JJS
cord-351517-npcuo1ld	103	28	for	for	IN
cord-351517-npcuo1ld	103	29	their	-PRON-	PRP$
cord-351517-npcuo1ld	103	30	patients	patient	NNS
cord-351517-npcuo1ld	103	31	.	.	.
cord-351517-npcuo1ld	104	1	Our	-PRON-	PRP$
cord-351517-npcuo1ld	104	2	bottom	bottom	JJ
cord-351517-npcuo1ld	104	3	line	line	NN
cord-351517-npcuo1ld	104	4	is	be	VBZ
cord-351517-npcuo1ld	104	5	some	some	DT
cord-351517-npcuo1ld	104	6	of	of	IN
cord-351517-npcuo1ld	104	7	these	these	DT
cord-351517-npcuo1ld	104	8	new	new	JJ
cord-351517-npcuo1ld	104	9	drugs	drug	NNS
cord-351517-npcuo1ld	104	10	are	be	VBP
cord-351517-npcuo1ld	104	11	important	important	JJ
cord-351517-npcuo1ld	104	12	advances	advance	NNS
cord-351517-npcuo1ld	104	13	such	such	JJ
cord-351517-npcuo1ld	104	14	as	as	IN
cord-351517-npcuo1ld	104	15	cyclosporine	cyclosporine	NN
cord-351517-npcuo1ld	104	16	,	,	,
cord-351517-npcuo1ld	104	17	mycophenolate	mycophenolate	NNP
cord-351517-npcuo1ld	104	18	mofetil	mofetil	NNP
cord-351517-npcuo1ld	104	19	and	and	CC
cord-351517-npcuo1ld	104	20	several	several	JJ
cord-351517-npcuo1ld	104	21	new	new	JJ
cord-351517-npcuo1ld	104	22	antibiotics	antibiotic	NNS
cord-351517-npcuo1ld	104	23	and	and	CC
cord-351517-npcuo1ld	104	24	anti	anti	JJ
cord-351517-npcuo1ld	104	25	-	-	JJ
cord-351517-npcuo1ld	104	26	fungal	fungal	JJ
cord-351517-npcuo1ld	104	27	drugs	drug	NNS
cord-351517-npcuo1ld	104	28	.	.	.
cord-351517-npcuo1ld	105	1	However	however	RB
cord-351517-npcuo1ld	105	2	,	,	,
cord-351517-npcuo1ld	105	3	the	the	DT
cord-351517-npcuo1ld	105	4	impact	impact	NN
cord-351517-npcuo1ld	105	5	of	of	IN
cord-351517-npcuo1ld	105	6	many	many	JJ
cord-351517-npcuo1ld	105	7	new	new	JJ
cord-351517-npcuo1ld	105	8	approved	approve	VBN
cord-351517-npcuo1ld	105	9	drugs	drug	NNS
cord-351517-npcuo1ld	105	10	on	on	IN
cord-351517-npcuo1ld	105	11	transplant	transplant	NN
cord-351517-npcuo1ld	105	12	outcomes	outcome	NNS
cord-351517-npcuo1ld	105	13	is	be	VBZ
cord-351517-npcuo1ld	105	14	mostly	mostly	RB
cord-351517-npcuo1ld	105	15	modest	modest	JJ
cord-351517-npcuo1ld	105	16	and	and	CC
cord-351517-npcuo1ld	105	17	not	not	RB
cord-351517-npcuo1ld	105	18	everyone	everyone	NN
cord-351517-npcuo1ld	105	19	needs	need	VBZ
cord-351517-npcuo1ld	105	20	them	-PRON-	PRP
cord-351517-npcuo1ld	105	21	.	.	.
cord-351517-npcuo1ld	106	1	Health	health	NN
cord-351517-npcuo1ld	106	2	care	care	NN
cord-351517-npcuo1ld	106	3	resources	resource	NNS
cord-351517-npcuo1ld	106	4	need	need	VBP
cord-351517-npcuo1ld	106	5	to	to	TO
cord-351517-npcuo1ld	106	6	be	be	VB
cord-351517-npcuo1ld	106	7	used	use	VBN
cord-351517-npcuo1ld	106	8	to	to	TO
cord-351517-npcuo1ld	106	9	reduce	reduce	VB
cord-351517-npcuo1ld	106	10	infant	infant	NN
cord-351517-npcuo1ld	106	11	mortality	mortality	NN
cord-351517-npcuo1ld	106	12	,	,	,
cord-351517-npcuo1ld	106	13	increase	increase	VB
cord-351517-npcuo1ld	106	14	childhood	childhood	NN
cord-351517-npcuo1ld	106	15	vaccination	vaccination	NN
cord-351517-npcuo1ld	106	16	rates	rate	NNS
cord-351517-npcuo1ld	106	17	,	,	,
cord-351517-npcuo1ld	106	18	eradicate	eradicate	VB
cord-351517-npcuo1ld	106	19	malaria	malaria	NN
cord-351517-npcuo1ld	106	20	etc	etc	FW
cord-351517-npcuo1ld	106	21	.	.	.
cord-351517-npcuo1ld	107	1	and	and	CC
cord-351517-npcuo1ld	107	2	most	most	RBS
cord-351517-npcuo1ld	107	3	recently	recently	RB
cord-351517-npcuo1ld	107	4	to	to	TO
cord-351517-npcuo1ld	107	5	combat	combat	VB
cord-351517-npcuo1ld	107	6	the	the	DT
cord-351517-npcuo1ld	107	7	SARS	SARS	NNP
cord-351517-npcuo1ld	107	8	-	-	HYPH
cord-351517-npcuo1ld	107	9	CoV-2	CoV-2	NNP
cord-351517-npcuo1ld	107	10	pandemic	pandemic	NN
cord-351517-npcuo1ld	107	11	and	and	CC
cord-351517-npcuo1ld	107	12	treat	treat	VB
cord-351517-npcuo1ld	107	13	COVID-19	COVID-19	NNP
cord-351517-npcuo1ld	107	14	;	;	:
cord-351517-npcuo1ld	107	15	these	these	DT
cord-351517-npcuo1ld	107	16	new	new	JJ
cord-351517-npcuo1ld	107	17	drugs	drug	NNS
cord-351517-npcuo1ld	107	18	are	be	VBP
cord-351517-npcuo1ld	107	19	unlikely	unlikely	JJ
cord-351517-npcuo1ld	107	20	to	to	TO
cord-351517-npcuo1ld	107	21	be	be	VB
cord-351517-npcuo1ld	107	22	the	the	DT
cord-351517-npcuo1ld	107	23	most	most	RBS
cord-351517-npcuo1ld	107	24	effective	effective	JJ
cord-351517-npcuo1ld	107	25	investment	investment	NN
cord-351517-npcuo1ld	107	26	of	of	IN
cord-351517-npcuo1ld	107	27	health	health	NN
cord-351517-npcuo1ld	107	28	care	care	NN
cord-351517-npcuo1ld	107	29	resources	resource	NNS
cord-351517-npcuo1ld	107	30	,	,	,
cord-351517-npcuo1ld	107	31	especially	especially	RB
cord-351517-npcuo1ld	107	32	in	in	IN
cord-351517-npcuo1ld	107	33	developing	develop	VBG
cord-351517-npcuo1ld	107	34	countries	country	NNS
cord-351517-npcuo1ld	107	35	.	.	.
cord-351517-npcuo1ld	108	1	Despite	despite	IN
cord-351517-npcuo1ld	108	2	the	the	DT
cord-351517-npcuo1ld	108	3	above	above	JJ
cord-351517-npcuo1ld	108	4	comments	comment	NNS
cord-351517-npcuo1ld	108	5	,	,	,
cord-351517-npcuo1ld	108	6	criticisms	criticism	NNS
cord-351517-npcuo1ld	108	7	and	and	CC
cord-351517-npcuo1ld	108	8	admonitions	admonition	NNS
cord-351517-npcuo1ld	108	9	we	-PRON-	PRP
cord-351517-npcuo1ld	108	10	are	be	VBP
cord-351517-npcuo1ld	108	11	standing	stand	VBG
cord-351517-npcuo1ld	108	12	by	by	RB
cord-351517-npcuo1ld	108	13	to	to	TO
cord-351517-npcuo1ld	108	14	renounce	renounce	VB
cord-351517-npcuo1ld	108	15	all	all	DT
cord-351517-npcuo1ld	108	16	of	of	IN
cord-351517-npcuo1ld	108	17	these	these	DT
cord-351517-npcuo1ld	108	18	potential	potential	JJ
cord-351517-npcuo1ld	108	19	liaisons	liaison	NNS
cord-351517-npcuo1ld	108	20	dangereuses	dangereuse	NNS
cord-351517-npcuo1ld	108	21	if	if	IN
cord-351517-npcuo1ld	108	22	a	a	DT
cord-351517-npcuo1ld	108	23	drug	drug	NN
cord-351517-npcuo1ld	108	24	company	company	NN
cord-351517-npcuo1ld	108	25	offers	offer	VBZ
cord-351517-npcuo1ld	108	26	to	to	TO
cord-351517-npcuo1ld	108	27	sponsor	sponsor	VB
cord-351517-npcuo1ld	108	28	us	-PRON-	PRP
cord-351517-npcuo1ld	108	29	to	to	TO
cord-351517-npcuo1ld	108	30	lecture	lecture	VB
cord-351517-npcuo1ld	108	31	on	on	IN
cord-351517-npcuo1ld	108	32	a	a	DT
cord-351517-npcuo1ld	108	33	new	new	JJ
cord-351517-npcuo1ld	108	34	drug	drug	NN
cord-351517-npcuo1ld	108	35	for	for	IN
cord-351517-npcuo1ld	108	36	transplant	transplant	NN
cord-351517-npcuo1ld	108	37	recipients	recipient	NNS
cord-351517-npcuo1ld	108	38	in	in	IN
cord-351517-npcuo1ld	108	39	Milano	Milano	NNP
cord-351517-npcuo1ld	108	40	with	with	IN
cord-351517-npcuo1ld	108	41	dinner	dinner	NN
cord-351517-npcuo1ld	108	42	at	at	IN
cord-351517-npcuo1ld	108	43	Cracco	Cracco	NNP
cord-351517-npcuo1ld	108	44	thrown	throw	VBN
cord-351517-npcuo1ld	108	45	in	in	IN
cord-351517-npcuo1ld	108	46	buon	buon	FW
cord-351517-npcuo1ld	108	47	appetito	appetito	NNP
cord-351517-npcuo1ld	108	48	.	.	.
cord-351517-npcuo1ld	109	1	Surrogate	surrogate	JJ
cord-351517-npcuo1ld	109	2	endpoints	endpoint	NNS
cord-351517-npcuo1ld	109	3	in	in	IN
cord-351517-npcuo1ld	109	4	oncology	oncology	NN
cord-351517-npcuo1ld	110	1	:	:	:
cord-351517-npcuo1ld	110	2	when	when	WRB
cord-351517-npcuo1ld	110	3	are	be	VBP
cord-351517-npcuo1ld	110	4	they	-PRON-	PRP
cord-351517-npcuo1ld	110	5	acceptable	acceptable	JJ
cord-351517-npcuo1ld	110	6	for	for	IN
cord-351517-npcuo1ld	110	7	regulatory	regulatory	JJ
cord-351517-npcuo1ld	110	8	and	and	CC
cord-351517-npcuo1ld	110	9	clinical	clinical	JJ
cord-351517-npcuo1ld	110	10	decisions	decision	NNS
cord-351517-npcuo1ld	110	11	,	,	,
cord-351517-npcuo1ld	110	12	and	and	CC
cord-351517-npcuo1ld	110	13	are	be	VBP
cord-351517-npcuo1ld	110	14	they	-PRON-	PRP
cord-351517-npcuo1ld	110	15	currently	currently	RB
cord-351517-npcuo1ld	110	16	overused	overuse	VBN
cord-351517-npcuo1ld	110	17	Cancer	Cancer	NNP
cord-351517-npcuo1ld	110	18	drugs	drug	NNS
cord-351517-npcuo1ld	110	19	approved	approve	VBN
cord-351517-npcuo1ld	110	20	on	on	IN
cord-351517-npcuo1ld	110	21	the	the	DT
cord-351517-npcuo1ld	110	22	basis	basis	NN
cord-351517-npcuo1ld	110	23	of	of	IN
cord-351517-npcuo1ld	110	24	a	a	DT
cord-351517-npcuo1ld	110	25	surrogate	surrogate	JJ
cord-351517-npcuo1ld	110	26	end	end	NN
cord-351517-npcuo1ld	110	27	point	point	NN
cord-351517-npcuo1ld	110	28	and	and	CC
cord-351517-npcuo1ld	110	29	subsequent	subsequent	JJ
cord-351517-npcuo1ld	110	30	overall	overall	JJ
cord-351517-npcuo1ld	110	31	survival	survival	NN
cord-351517-npcuo1ld	110	32	.	.	.
cord-351517-npcuo1ld	111	1	An	an	DT
cord-351517-npcuo1ld	111	2	analysis	analysis	NN
cord-351517-npcuo1ld	111	3	of	of	IN
cord-351517-npcuo1ld	111	4	5	5	CD
cord-351517-npcuo1ld	111	5	years	year	NNS
cord-351517-npcuo1ld	111	6	of	of	IN
cord-351517-npcuo1ld	111	7	US	US	NNP
cord-351517-npcuo1ld	111	8	Food	Food	NNP
cord-351517-npcuo1ld	111	9	and	and	CC
cord-351517-npcuo1ld	111	10	Drug	Drug	NNP
cord-351517-npcuo1ld	111	11	Administration	Administration	NNP
cord-351517-npcuo1ld	111	12	approvals	approval	VBZ
cord-351517-npcuo1ld	111	13	Availability	availability	NN
cord-351517-npcuo1ld	111	14	of	of	IN
cord-351517-npcuo1ld	111	15	evidence	evidence	NN
cord-351517-npcuo1ld	111	16	of	of	IN
cord-351517-npcuo1ld	111	17	benefits	benefit	NNS
cord-351517-npcuo1ld	111	18	on	on	IN
cord-351517-npcuo1ld	111	19	overall	overall	JJ
cord-351517-npcuo1ld	111	20	survival	survival	NN
cord-351517-npcuo1ld	111	21	and	and	CC
cord-351517-npcuo1ld	111	22	quality	quality	NN
cord-351517-npcuo1ld	111	23	of	of	IN
cord-351517-npcuo1ld	111	24	life	life	NN
cord-351517-npcuo1ld	111	25	of	of	IN
cord-351517-npcuo1ld	111	26	cancer	cancer	NN
cord-351517-npcuo1ld	111	27	drugs	drug	NNS
cord-351517-npcuo1ld	111	28	approved	approve	VBN
cord-351517-npcuo1ld	111	29	by	by	IN
cord-351517-npcuo1ld	111	30	European	European	NNP
cord-351517-npcuo1ld	111	31	Medicines	Medicines	NNPS
cord-351517-npcuo1ld	111	32	Agency	Agency	NNP
cord-351517-npcuo1ld	111	33	:	:	:
cord-351517-npcuo1ld	111	34	retrospective	retrospective	JJ
cord-351517-npcuo1ld	111	35	cohort	cohort	NN
cord-351517-npcuo1ld	111	36	study	study	NN
cord-351517-npcuo1ld	111	37	of	of	IN
cord-351517-npcuo1ld	111	38	drug	drug	NN
cord-351517-npcuo1ld	111	39	approvals	approval	NNS
cord-351517-npcuo1ld	111	40	2009	2009	CD
cord-351517-npcuo1ld	111	41	-	-	SYM
cord-351517-npcuo1ld	111	42	13	13	CD
cord-351517-npcuo1ld	111	43	Uses	use	NNS
cord-351517-npcuo1ld	111	44	and	and	CC
cord-351517-npcuo1ld	111	45	limitations	limitation	NNS
cord-351517-npcuo1ld	111	46	of	of	IN
cord-351517-npcuo1ld	111	47	the	the	DT
cord-351517-npcuo1ld	111	48	restricted	restricted	JJ
cord-351517-npcuo1ld	111	49	mean	mean	JJ
cord-351517-npcuo1ld	111	50	survival	survival	NN
cord-351517-npcuo1ld	111	51	time	time	NN
cord-351517-npcuo1ld	111	52	:	:	:
cord-351517-npcuo1ld	111	53	illustrative	illustrative	JJ
cord-351517-npcuo1ld	111	54	examples	example	NNS
cord-351517-npcuo1ld	111	55	from	from	IN
cord-351517-npcuo1ld	111	56	cardiovascular	cardiovascular	JJ
cord-351517-npcuo1ld	111	57	outcomes	outcome	NNS
cord-351517-npcuo1ld	111	58	and	and	CC
cord-351517-npcuo1ld	111	59	mortality	mortality	NN
cord-351517-npcuo1ld	111	60	trials	trial	NNS
cord-351517-npcuo1ld	111	61	in	in	IN
cord-351517-npcuo1ld	111	62	type	type	NN
cord-351517-npcuo1ld	111	63	2	2	CD
cord-351517-npcuo1ld	111	64	diabetes	diabetes	NN
cord-351517-npcuo1ld	111	65	Midostaurin	Midostaurin	NNP
cord-351517-npcuo1ld	111	66	plus	plus	CC
cord-351517-npcuo1ld	111	67	chemotherapy	chemotherapy	NN
cord-351517-npcuo1ld	111	68	for	for	IN
cord-351517-npcuo1ld	111	69	acute	acute	JJ
cord-351517-npcuo1ld	111	70	myeloid	myeloid	JJ
cord-351517-npcuo1ld	111	71	leukemia	leukemia	NN
cord-351517-npcuo1ld	111	72	with	with	IN
cord-351517-npcuo1ld	111	73	a	a	DT
cord-351517-npcuo1ld	111	74	FLT3	FLT3	NNP
cord-351517-npcuo1ld	111	75	mutation	mutation	NN
cord-351517-npcuo1ld	112	1	What	what	WP
cord-351517-npcuo1ld	112	2	is	be	VBZ
cord-351517-npcuo1ld	112	3	the	the	DT
cord-351517-npcuo1ld	112	4	P	p	NN
cord-351517-npcuo1ld	112	5	-	-	HYPH
cord-351517-npcuo1ld	112	6	value	value	NN
cord-351517-npcuo1ld	112	7	anyway	anyway	RB
cord-351517-npcuo1ld	112	8	?	?	.
cord-351517-npcuo1ld	113	1	What	what	WP
cord-351517-npcuo1ld	113	2	is	be	VBZ
cord-351517-npcuo1ld	113	3	the	the	DT
cord-351517-npcuo1ld	113	4	(	(	-LRB-
cord-351517-npcuo1ld	113	5	p-	p-	NN
cord-351517-npcuo1ld	113	6	)	)	-RRB-
cord-351517-npcuo1ld	113	7	value	value	NN
cord-351517-npcuo1ld	113	8	of	of	IN
cord-351517-npcuo1ld	113	9	the	the	DT
cord-351517-npcuo1ld	113	10	pvalue	pvalue	NNS
cord-351517-npcuo1ld	113	11	?	?	.
cord-351517-npcuo1ld	114	1	Following	follow	VBG
cord-351517-npcuo1ld	114	2	the	the	DT
cord-351517-npcuo1ld	114	3	script	script	NN
cord-351517-npcuo1ld	114	4	:	:	:
cord-351517-npcuo1ld	114	5	how	how	WRB
cord-351517-npcuo1ld	114	6	drug	drug	NN
cord-351517-npcuo1ld	114	7	reps	rep	NNS
cord-351517-npcuo1ld	114	8	make	make	VBP
cord-351517-npcuo1ld	114	9	friends	friend	NNS
cord-351517-npcuo1ld	114	10	and	and	CC
cord-351517-npcuo1ld	114	11	influence	influence	VB
cord-351517-npcuo1ld	114	12	doctors	doctor	NNS
cord-351517-npcuo1ld	114	13	Research	Research	NNP
cord-351517-npcuo1ld	114	14	and	and	CC
cord-351517-npcuo1ld	114	15	development	development	NN
cord-351517-npcuo1ld	114	16	spending	spending	NN
cord-351517-npcuo1ld	114	17	to	to	TO
cord-351517-npcuo1ld	114	18	bring	bring	VB
cord-351517-npcuo1ld	114	19	a	a	DT
cord-351517-npcuo1ld	114	20	single	single	JJ
cord-351517-npcuo1ld	114	21	cancer	cancer	NN
cord-351517-npcuo1ld	114	22	drug	drug	NN
cord-351517-npcuo1ld	114	23	to	to	IN
cord-351517-npcuo1ld	114	24	market	market	NN
cord-351517-npcuo1ld	114	25	and	and	CC
cord-351517-npcuo1ld	114	26	revenues	revenue	NNS
cord-351517-npcuo1ld	114	27	after	after	IN
cord-351517-npcuo1ld	114	28	approval	approval	NN
cord-351517-npcuo1ld	114	29	Comparison	comparison	NN
cord-351517-npcuo1ld	114	30	of	of	IN
cord-351517-npcuo1ld	114	31	industry	industry	NN
cord-351517-npcuo1ld	114	32	payments	payment	NNS
cord-351517-npcuo1ld	114	33	in	in	IN
cord-351517-npcuo1ld	114	34	2017	2017	CD
cord-351517-npcuo1ld	114	35	with	with	IN
cord-351517-npcuo1ld	114	36	annual	annual	JJ
cord-351517-npcuo1ld	114	37	salary	salary	NN
cord-351517-npcuo1ld	114	38	in	in	IN
cord-351517-npcuo1ld	114	39	a	a	DT
cord-351517-npcuo1ld	114	40	cohort	cohort	NN
cord-351517-npcuo1ld	114	41	of	of	IN
cord-351517-npcuo1ld	114	42	academic	academic	JJ
cord-351517-npcuo1ld	114	43	oncologists	oncologist	NNS
cord-351517-npcuo1ld	115	1	Acknowledgements	acknowledgement	NNS
cord-351517-npcuo1ld	115	2	RPG	RPG	NNP
cord-351517-npcuo1ld	115	3	acknowledges	acknowledge	VBZ
cord-351517-npcuo1ld	115	4	support	support	NN
cord-351517-npcuo1ld	115	5	from	from	IN
cord-351517-npcuo1ld	115	6	the	the	DT
cord-351517-npcuo1ld	115	7	National	National	NNP
cord-351517-npcuo1ld	115	8	Institute	Institute	NNP
cord-351517-npcuo1ld	115	9	of	of	IN
cord-351517-npcuo1ld	115	10	Health	Health	NNP
cord-351517-npcuo1ld	115	11	Research	Research	NNP
cord-351517-npcuo1ld	115	12	(	(	-LRB-
cord-351517-npcuo1ld	115	13	NIHR	NIHR	NNP
cord-351517-npcuo1ld	115	14	)	)	-RRB-
cord-351517-npcuo1ld	115	15	Biomedical	Biomedical	NNP
cord-351517-npcuo1ld	115	16	Research	Research	NNP
cord-351517-npcuo1ld	115	17	Centre	Centre	NNP
cord-351517-npcuo1ld	115	18	funding	funding	NN
cord-351517-npcuo1ld	115	19	scheme	scheme	NN
cord-351517-npcuo1ld	115	20	.	.	.